FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches.

1. Introduction

The amide functional group plays a pivotal role in the composition of biomolecules, including many clinically approved drugs. Amide bonds are found in many natural compounds and popular drugs, which makes this functional group one of the most abundant in organic chemistry. Chemically speaking, an amide bond is a covalent linkage formed between a carboxyl group and an amino group, and it is the key structural feature of peptides and proteins. Structurally, in the case of a secondary amide, the bond consists of a carbonyl carbon (C=O) bonded to a nitrogen atom (–NH–), giving the characteristic of a –CO–NH– linkage. In primary amides, the nitrogen is bonded to the carbonyl carbon and two hydrogen atoms. In tertiary amides, the nitrogen is bonded to the carbonyl carbon and two alkyl/aryl groups (with no hydrogens). Over the past five years, significant advancements have been made in the activation of amides through complementary mechanisms that ultimately depend on ground-state destabilization of the amide linkage, despite the fact that typical amides are planar and the amide N–C(O) bond is notoriously difficult to break due to n N →π ⁎ C=O resonance [ 1 ].

Among natural compounds, compounds with amide function exhibit a wide spectrum of biological action. The pungency of black pepper, for example, is generated by the alkaloid piperine and its isomer chavicine [ 2 , 3 ] (with both containing cyclic amide groups 1 and 2 ; Figure 1 ). Capsaicin ( 3 ; Figure 1 ) is the principal active component of chili peppers and gives them their “spicy” or “hot” flavor [ 4 , 5 ]. Nicotinamide ( 4 ; Figure 1 ) is a naturally occurring form of Vitamin B3, essential for metabolic processes [ 6 , 7 ]. Another class containing amide bonds is represented by peptides. Peptides are formed through amide bonds, also known as peptide bonds, which are the fundamental chemical linkages holding amino acids together. An amide bond is created when the carboxyl group (–COOH) of one amino acid reacts with the amino group (–NH 2 ) of another, releasing a molecule of water in a condensation reaction [ 8 ]. This bond gives peptides their characteristic backbone structure, providing both stability and flexibility [ 9 ]. Because the amide bond is chemically robust yet capable of participating in hydrogen bonding, peptides can adopt the diverse three-dimensional shapes essential for their biological functions [ 10 ]. As a result, peptides are widespread in nature, forming the structural and functional basis of proteins involved in nearly all biological processes, including enzymes, hormones, signaling molecules, and structural components of cells [ 11 , 12 ]. The unique properties of the amide bond, its planarity, partial double-bond character, and resistance to spontaneous breakdown explain why peptides are so prevalent and reliable as molecular building blocks in living systems [ 10 ]. Among natural peptides is proctolin ( 5 ; Figure 1 ), a pentapeptide that is present in insects and crustaceans and acts as a neuromodulator and possibly as a neurohormone [ 13 ]. Found in mammals, tuftsin ( 6 ; Figure 1 ) is derived from immunoglobulin G (IgG) and plays an important role in immune response, especially in activating macrophages and neutrophils [ 14 ]. Oxytocin ( 7 ; Figure 1 ) is a peptide made up of nine amino acids. It is a reproductive hormone and is used to induce labor and control postpartum bleeding [ 15 ].

Moving to pharmaceuticals, the amide group improves stability, binding to target proteins, and mimicry of peptide bonds, helping these compounds act effectively as analgesics, antibiotics, anesthetics, CNS drugs, cardiovascular agents, and agrochemicals, as demonstrated by paracetamol ( 8 ), lidocaine ( 9 ), amoxicillin ( 10 ), diazepam ( 11 ), and captopril ( 12 ), see Figure 2 .

Paracetamol (acetaminophen) acts primarily as a central nervous system (CNS) analgesic by reducing pain signaling in the brain and spinal cord [ 16 , 17 ]. Lidocaine is a widely used, effective local anesthetic and anti-inflammatory agent for rapid, short-term pain relief, commonly used in topical patches, creams, and IV infusions [ 18 ]. Amoxicillin is a widely used, bactericidal beta-lactam (four-membered lactam) antibiotic in the aminopenicillin family, designed to treat a broad spectrum of Gram-positive and Gram-negative bacteria [ 19 ]. Diazepam is a member of the benzodiazepine class, introduced in the 1960s. They are relatively safe drugs, in comparison with other types of drugs used to treat anxiety [ 20 ]. Captopril is an ACE inhibitor medication used to treat high blood pressure (hypertension), heart failure, and damage after a heart attack by relaxing blood vessels [ 21 ].

Figure 3 a illustrates a generally upward trend in the number of search results on PubMed for “amide bond” from the year 2000 through 2026, reaching a peak of around 700 results annually in the years 2014–2022 [ 22 ]. The visual trend is consistent with search results indicating a growing interest and the significant role of the amide bond in medicinal chemistry, drug development, and organic synthesis, particularly in recent decades. The formation of amide bonds is one of the most frequently performed reactions in both academic and industrial settings. Moreover, amide biocatalysis and its formation in flow is a rapidly advancing, high-impact field that merges the high selectivity of enzymes with the superior process engineering of continuous-flow chemistry, and many reviews have covered this topic widely [ 23 , 24 , 25 ]. Figure 3 b [ 26 ] focuses specifically on drugs containing amide functionalities, allowing for a more targeted assessment of the relevance of amide bonds in medicinal chemistry and drug development. This refinement helps distinguish general chemical usage from trends directly related to therapeutic applications. It is interesting to note that a stable interest in this field and a decline in the period 2021–2023 are probably due to the COVID-19 pandemic.

2. FDA-Approved Drugs in 2021–2025 Containing Amide Group

In the next section, we will focus on the FDA-approved drugs (<1300 Da) that contain at least an amide functional group, excluding carbamates, sulfamides, and urea, despite these being closely related to amide. This topic has also been addressed in the review ‘A Perspective of the Amide Group Containing FDA Approved Anticancer Drugs from 2021–2022’ by Nasibullah [ 27 ]; however, our work differs by focusing on covering all the small molecules that contain an amide group in the period 2020–2025. When possible, the role of the amide linkage will be explained.

2.1. FDA-Approved Drugs in 2021 Containing Amide Group

In 2021, the FDA approved a total of 50 drugs, of which 36 were new chemical entities [ 28 ]. The approved drugs addressed a broad range of therapeutic areas, including oncology, infectious diseases, and rare disorders, reflecting ongoing efforts to meet unmet medical needs. The diversity of chemical structures among the NCEs, many of which contain key functional groups such as amides, underscores the importance of functional group chemistry in modern drug design and development. In the following sections, amide-containing small molecules will be presented.

2.1.1. Pafolacianine

Pafolacianine ( 13 , Figure 4 a), marketed under the brand name Cytalux ® , is a fluorescent optical imaging agent that was approved by the U.S. Food and Drug Administration (FDA) on 29 November 2021 for use in adult patients with ovarian cancer as an adjunct to help surgeons identify malignant lesions during surgery [ 29 ]. This approval marked the first FDA authorization of pafolacianine for intraoperative tumor detection, leveraging its ability to bind to folate receptors that are often overexpressed on ovarian cancer cells and to emit fluorescence under near-infrared light [ 30 ]. The decision was based on clinical evidence showing that the agent enabled the detection of additional cancerous tissue beyond what is visible with standard surgical inspection techniques, thereby potentially improving surgical outcomes [ 31 ]. The structure is a large, complex organic molecule composed of multiple aromatic and heteroaromatic ring systems linked by flexible aliphatic chains. Two amide functional groups are present, contributing to molecular rigidity, resonance stabilization, and hydrogen-bonding capability. A folate analog (on the left portion of the molecule) is linked to a tyrosine amino acid through an amide linkage ( Figure 4 b) [ 29 ]. The molecule also contains sulfonic acid groups, which introduce strong polarity and a negative charge, significantly enhancing aqueous solubility. Multiple heterocycles containing nitrogen atoms are incorporated, increasing the potential for specific biological interactions through hydrogen bonding and electrostatic forces. Phenyl and fused aromatic systems provide hydrophobic regions, creating an amphiphilic character with distinct polar and nonpolar domains. Overall, the chemical architecture reflects a balance between aromatic hydrophobic scaffolds and strongly polar, ionizable functional groups, a design well suited for biological targeting. The amide linker is introduced via a HATU/DIPEA coupling strategy ( Figure 4 c) starting from triflouroacetylpteroic acid as the starting material ( INT1 ) and (O t Bu)-protected tyrosine, affording INT2 in 96% yield [ 32 ].

2.1.2. Asciminib

Asciminib ( 14 , brand name Scemblix ® , Figure 5 a) is an FDA-approved targeted therapy for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. It was first granted accelerated approval by the FDA on 29 October 2021 for adult patients with Ph+ CML in chronic phase who had received two or more prior tyrosine kinase inhibitors, and for patients with the T315I mutation, which is associated with treatment resistance [ 33 , 34 ]. Asciminib represents a novel class of tyrosine kinase inhibitor that uniquely binds to the myristoyl pocket of the BCR-ABL1 fusion protein, a distinct mechanism compared with other TKIs that target the ATP binding site, thereby potentially overcoming resistance seen with earlier therapies [ 35 ]. Clinically, asciminib has demonstrated improved major molecular response rates and a favorable safety profile in randomized trials versus standard therapy, offering an important option for patients with difficult-to-treat CML [ 36 ]. Chemically, asciminib is a small-molecule, heteroaromatic compound containing multiple nitrogen-rich ring systems and one amide functional group, which contributes to its polarity and hydrogen-bonding capability. The structure incorporates a benzamide moiety that has been linked with enhanced potency and kinase selectivity [ 37 ]. Overall, asciminib exhibits a balanced amphiphilic character, combining polar functional groups for target recognition with hydrophobic scaffolding for effective pharmacokinetic behavior. The preparation of INT4 , an intermediate in the synthesis of asciminib, is obtained via activation of carboxylic acid ( INT3 ) using thionyl chloride and 4-(chlorodifluoromethoxy)aniline to give the amide building block in 77% yield [ 38 ].

2.1.3. Avacopan

Approved on 7 October 2021, avacopan ( 15 , brand name Tavneos ® , Figure 6 a) is a small-molecule oral drug that selectively blocks the complement 5a receptor (C5aR), part of the immune system involved in inflammation. By antagonizing C5aR, it helps reduce neutrophil-mediated inflammation in small blood vessels [ 39 , 40 ]. It is used as an adjunctive treatment (added to standard immunosuppressive therapy, including glucocorticoids) for adults with ANCA-associated vasculitis [ 39 , 40 ]. Moving to its chemistry, the combination of a rigid core, aromatic hydrophobic regions, fluorinated substituents, and strategically placed amide groups (two) reflects a classic medicinal-chemistry design for a potent, selective, and orally active C5aR antagonist. The synthesis of avacopan ( Figure 6 b) is accomplished via coupling the ethyl ester ( INT5 ) using AlMe 3 -mediated direct coupling with 4-methyl-5-trifluoromethylaniline to give the desired drug in good yield (80%) [ 32 ].

2.1.4. Atogepant

Atogepant ( 16 , brand names Qulipta ® and Aquipta ® , Figure 7 a) is an orally administered, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist in the “gepant” class, developed primarily for preventive treatment of migraine headaches in adults [ 41 , 42 ]. It works by blocking the CGRP receptor, reducing CGRP-mediated neurogenic inflammation, vasodilation, and nociceptive signaling that contribute to migraine pathophysiology. This targeted mechanism helps lower the frequency of migraine days when taken once daily in doses such as 10 mg, 30 mg, or 60 mg tablets [ 43 , 44 ]. The structure is a complex, stereochemically defined small molecule built around multiple heterocycles and three amide linkages, indicating a highly optimized, target-specific design. A rigid fused heteroaromatic core on the left likely serves as a key binding motif, while the central heteroaryl and amide connectors balance rigidity with controlled flexibility. The fluorinated aromatic ring and CF 3 /difluoro substituents on the right enhance lipophilicity, metabolic stability, and binding affinity. Overall, the molecule shows a deliberate balance of polarity, rigidity, and a three-dimensional shape typical of a late-stage medicinal chemistry lead or clinical candidate. The final step of preparation for atogepant ( Figure 7 b) involves a condensation between amine ( INT7 ) and carboxylic acid INT8 via the EDC/HOBt coupling reagent [ 32 ].

2.1.5. Mobocertinib

Approved by the FDA on 15 September 2021, mobocertinib ( 17 , brand name Exkivity ® , Figure 8 a) is an oral, small-molecule tyrosine kinase inhibitor designed to selectively target epidermal growth factor receptor (EGFR) exon 20 insertion mutations in non-small-cell lung cancer (NSCLC), a subset that is poorly responsive to other EGFR inhibitors [ 45 ]. It covalently and irreversibly inhibits mutant EGFR (and related family kinases) to block signaling that drives tumor growth. Mobocertinib was granted accelerated approval by the FDA and is indicated for adults with locally advanced or metastatic EGFR exon 20 insertion-positive NSCLC after platinum-based chemotherapy [ 46 ]. In pivotal trials, it showed meaningful antitumor activity with objective response rates in previously treated patients and median progression-free survival in the range seen for targeted therapies, although confirmatory trials are required to maintain approval. Common adverse effects include diarrhea, rash, nausea, and other gastrointestinal and skin toxicities [ 47 ]. The most functionally significant feature of this structure is the acrylamide warhead, which is a hallmark of covalent kinase inhibitors. The α,β-unsaturated carbonyl acts as a Michael acceptor, enabling selective, irreversible covalent bonding with a nucleophilic cysteine residue in the target protein (classically in EGFR-family kinases) [ 48 ]. This transforms the molecule from a reversible binder into a targeted covalent inhibitor, increasing potency, duration of action, and target residence time. Importantly, the acrylamide is positioned at the end of a flexible linker, allowing precise geometric alignment with the cysteine in the binding pocket, which improves selectivity and reduces off-target reactivity. Mobocertinib ( Figure 8 b) was synthesized in an 89% yield starting from INT9 and 3-(phenylsulfonyl)propanoic acid. This process was driven by propylphosphonic anhydride (T3P)-mediated coupling, followed by the elimination of the phenylsulfonyl group using potassium trimethylsilanolate [ 45 ].

2.1.6. Odevixibat

Odevixibat ( 18 , brand name Bylvay ® , Figure 9 a) is an oral ileal bile acid transporter (IBAT) inhibitor developed for the treatment of rare pediatric cholestatic liver diseases [ 49 ]. By blocking bile acid reabsorption in the terminal ileum, it reduces systemic bile acid levels, which are responsible for liver injury and severe pruritus in these conditions [ 50 , 51 ]. In the United States, odevixibat was approved by the FDA in July 2021 for the treatment of pruritus in patients aged three months and older with progressive familial intrahepatic cholestasis (PFIC) [ 49 ]. This approval was based on clinical trials demonstrating significant reductions in serum bile acids and improvements in itch severity. Its chemical structure is characterized by a central benzothiadiazepine core linked to a peptide-like side chain (two amide bonds are counted). Odevixibat is a relatively large, flexible molecule with a mixed polarity profile. It contains multiple polar functionalities (amide, carboxylic acid, heteroatoms capable of hydrogen bonding) alongside a substantial hydrophobic component. This means it is neither purely hydrophilic nor purely lipophilic. Regarding the synthetic preparation ( Figure 9 b), the deprotection of tert-butyl ester INT10 using trifluoroacetic acid (TFA) in dichloromethane, followed by a second peptide coupling with tert-butyl ( S )-2-aminobutanoate, yielded dipeptide INT11 . Subsequent acidic hydrolysis of intermediate INT11 then afforded the target compound, odevixibat ( 18 ) [ 32 ].

2.1.7. Belumosudil

Approved on 16 July 2021, belumosudil ( 19 , brand name Rezurock ® , Figure 10 a) is an oral small-molecule drug approved by the U.S. FDA for the treatment of adults and pediatric patients 12 years of age and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy [ 52 , 53 ]. It works by selectively inhibiting Rho-associated coiled-coil-containing protein kinase 2 (ROCK2), a signaling enzyme involved in immune dysregulation and fibrosis [ 54 ]. By targeting ROCK2, belumosudil helps rebalance pro-inflammatory and regulatory immune pathways while also reducing fibrotic processes that contribute to organ damage in cGVHD [ 55 ]. Clinical studies showed meaningful overall response rates across multiple affected organs, with many patients experiencing durable responses and improvements in symptoms [ 56 ]. The drug is generally well tolerated, with common side effects including fatigue, diarrhea, nausea, cough, and infections [ 57 ], making it a targeted therapeutic option for patients with difficult-to-treat chronic GVHD. The molecule is a polycyclic heteroaromatic compound with multiple fused and linked aromatic rings. It contains a quinazoline-like core connected via a secondary amine to a benzimidazole-type ring, along with a substituted phenyl ring bearing an ether side chain that terminates in a secondary amide. The structure includes several nitrogen heterocycles, aromatic systems, and an isopropyl-substituted amide. Among the different synthetic routes for belumosudil, herein is presented one efficient procedure taken from a patent ( Figure 10 b) [ 58 ]. Belumosudil ( 16 ) is constructed through selective peptide coupling. The carboxylic acid intermediate INT12 is activated using the phosphonium reagent PyBOP and the non-nucleophilic base DIPEA, which facilitates a smooth nucleophilic substitution by isopropylamine to afford the target drug in a 61% yield.

2.1.8. Finerenone

Approved on 9 July 2021, finerenone ( 20 , brand name Kerendia ® , Figure 11 a) is a nonsteroidal mineralocorticoid receptor antagonist used to reduce the risk of chronic kidney disease progression and cardiovascular events in adults with chronic kidney disease associated with type 2 diabetes [ 59 , 60 ]. It works by selectively blocking mineralocorticoid receptor-mediated inflammation and fibrosis, offering renal and cardiovascular protection with a lower risk of hormonal side effects compared to older agents [ 60 ]. The structure is a polycyclic, aromatic-rich molecule featuring a fused heterocyclic core linked to a substituted phenyl ring. It contains multiple nitrogen functionalities, including a heteroaromatic ring nitrogen, a secondary amine, an amide group, and a nitrile substituent. Oxygen-containing groups include ether linkages and a methoxy substituent, contributing to polarity and hydrogen-bonding capacity. The final step to obtain finerenone is presented in Figure 11 b. The corresponding ethyl ester INT13 undergoes aminolysis using ammonia (an aqueous solution, dissolved in an alcohol like methanol). The reaction temperature in this step is 0 °C to room temperature, preferably 0 °C to 10 °C, and the reaction time is 10 to 20 h, preferably 16 to 20 h [ 61 ].

2.1.9. Samidorphan

Approved on 28 May 2021, Lybalvi ® ( Figure 12 a), a fixed-dose combination of olanzapine ( 21 ) and samidorphan ( 22 ), was indicated for the treatment of schizophrenia and bipolar I disorder. Samidorphan is included to mitigate olanzapine-associated weight gain while preserving the antipsychotic efficacy of olanzapine, improving the overall metabolic safety profile [ 62 , 63 ]. Only samidorphan contains an amide moiety. The preparation of the intermediate containing an amide ( Figure 12 b) in samidorphan starts with protection of the ketone ( INT14 ) with ethylene glycol and p-TSA to form a cyclic ketal protecting group, preventing it from interfering with later steps. Next, the activation of the phenol on the aromatic ring is reacted with PhNTf 2 and TEA to convert it into a triflate, turning a poor leaving group into an excellent one ( INT15 ). Eventually, INT15 undergoes palladium-catalyzed cross-coupling using Pd(OAc) 2 and 1,1′-Bis(diphenylphosphino)ferrocene (dppf). In the presence of carbon monoxide (gaseous CO) and ammonia, the triflate is replaced by a primary carboxamide group to yield the final product ( INT16 ) [ 64 ].

2.1.10. Sotorasib

Approved on 28 May 2021, sotorasib ( 23 , brand name Lumakras ® , Figure 13 a) is the first targeted therapy for patients with a KRAS mutation, specifically the G12C variant, which was previously considered an “undruggable” target in oncology [ 65 ]. Sotorasib works by irreversibly and selectively binding to the inactive GDP-bound state of the mutant KRAS G12C protein, effectively locking it into an inactive form to block downstream signaling pathways that drive tumor growth [ 66 ]. The acrylamide group of sotorasib is an electrophilic warhead that can freely react with nucleophiles such as thiol and amine groups [ 67 ]. The installation of an acrylic group on an amine ( INT17 ) was accomplished via acryloyl chloride in NMP ( Figure 13 b) [ 68 ].

2.1.11. Piflufolastat F 18

Approved on 27 May 2021, piflufolastat F 18 ( 24 , brand name Pylarify ® , Figure 14 a) is a radioactive diagnostic agent used in PET/CT imaging to detect prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. It is specifically for identifying suspected metastasis before initial treatment or detecting recurrent cancer based on elevated PSA levels [ 69 , 70 ]. Its chemistry revolves around a highly specific urea-based scaffold designed to inhibit the prostate-specific membrane antigen (PSMA) [ 71 ]. The synthesis ( Figure 14 b) originates from Nε-Boc-Nα-Fmoc-l-lysine ( INT18 ), which first protects acidic functionality with p -methoxy benzyl chloride, and secondly, Fmoc is cleaved by using a 20% piperidine solution to afford the derivative INT19 . Urea INT21 was obtained by treating bis-4-methoxybenzyl-l-glutamate·HCl ( INT20 ) with triphosgene and triethylamine at −80 °C, followed by in situ trapping of the isocyanate intermediate by the addition of INT20 [ 72 ].

2.1.12. Serdexmethylphenidate

Azstarys ® ( Figure 15 a, the combined formulation of serdexmethylphenidate 25 and dexmethylphenidate 26 ) was approved by the U.S. Food and Drug Administration (FDA) in March 2021 for medical use in the United States for the once-daily treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged 6 years and older [ 73 , 74 ]. Azstarys ® is a central nervous system (CNS) stimulant that pairs immediate-release dexmethylphenidate with serdexmethylphenidate, a prodrug that gradually converts to dexmethylphenidate after ingestion, aiming to provide a rapid onset and extended duration of symptom control throughout the day [ 75 ]. The released dexmethylphenidate then inhibits the reuptake of dopamine and norepinephrine by blocking the dopamine transporter (DAT) and norepinephrine transporter (NET) in the central nervous system, increasing the availability of these neurotransmitters in synaptic clefts—particularly in the prefrontal cortex [ 76 ]. Serdexmethylphenidate contains a hydrolyzable ester bond that links the dexmethylphenidate core to its promoiety, which is essential for its function as a prodrug. This ester bond (specifically a carbamate ester) is gradually cleaved by enzymatic hydrolysis after oral administration, releasing the active dexmethylphenidate. Synthetically, reaction of methyl (R)-2-phenyl-2-((R)-piperidin-2-yl)acetate hydrochloride INT22 with chloromethyl chloroformate using DIPEA as a base generated the carbamate INT23 in quantitative yield ( Figure 15 b) [ 32 ].

2.1.13. Melphalan Flufenamide

Approved on 26 February 2021, melphalan flufenamide ( 27 , brand name Pepaxto ® , Figure 16 a) is a peptide-based drug designed to deliver the alkylating agent melphalan ( 28 ) preferentially into cancer cells with high aminopeptidase activity [ 77 ]. It received accelerated FDA approval in combination with dexamethasone for adults with heavily pretreated relapsed or refractory multiple myeloma based on response rates from the phase 2 HORIZON trial [ 78 ]. However, subsequent confirmatory data did not demonstrate a favorable benefit–risk profile, and the FDA withdrew its approval in February 2024 [ 79 ].

Melphalan flufenamide is designed as a prodrug. Melphalan itself is polar and enters cells relatively inefficiently. By linking melphalan to a short peptide via an amide bond, the molecule becomes more lipophilic, allowing it to cross cell membranes much more easily [ 80 ]. Melphalan flufenamide is a neutral, relatively lipophilic prodrug with aromatic and amide/ester functionalities, which makes it preferentially soluble in polar aprotic solvents. The synthesis of synthon ( INT26 ), important for the synthesis of melphalan flufenamide, is accomplished via condensation (EDC/HOBt) between amine ( INT24 ) and (S)-2-((tert-butoxycarbonyl)amino)-3-(4-nitrophenyl)propanoic acid ( INT25 ) in a good yield (89%, Figure 16 b) [ 32 ].

2.1.14. Fosdenopterin

Approved on 26 February 2021, fosdenopterin ( 29 , brand name Nulibry ® , Figure 17 ) is a medicine that has been studied largely for its ability to treat molybdenum cofactor deficiency (MCD), a rare metabolic condition. This disorder is caused by a deficiency in the creation of molybdenum cofactor, which is required for the proper functioning of several essential enzymes [ 81 ]. Chemically, fosdenopterin has a carbonyl within the pterin heterocycle (a pteridin-4-one), but this is part of an aromatic heterocyclic ring system (lactam-like), not a discrete –C(=O)–NH– amide linkage. The amide linkage was already established in the primary building blocks, shifting the synthetic focus toward peripheral modifications.

2.1.15. Trilaciclib

Approved on 12 February 2021, trilaciclib ( 30 , brand name Cosela ® , Figure 18 a) is a small-molecule cyclin-dependent kinase (CDK) 4/6 inhibitor developed by G1 Therapeutics that is used to decrease the incidence of chemotherapy-induced myelosuppression in adult patients receiving certain chemotherapeutic regimens for extensive-stage small cell lung cancer (ES-SCLC) by transiently arresting hematopoietic stem and progenitor cells in G1 phase, protecting bone marrow from damage [ 82 , 83 ]. The key synthetic step to form the lactam is presented in Figure 18 b. First, the formyl group on INT27 is oxidized to a carboxylic acid using Oxone in DMF. Following this, trifluoroacetic acid (TFA) cleaves the tert -butyloxycarbonyl (Boc) protecting group to liberate the primary amine. Finally, the coupling reagent DCC and catalyst DMAP facilitate an intramolecular amide bond formation between the newly generated carboxylic acid and the free amine. This lactamization sequence successfully closes the seven-membered ring, yielding the spirocyclic architecture seen in INT28 [ 84 ].

2.1.16. Tepotinib

Approved on 3 February 2021, tepotinib ( 31 , brand name Tepmetko ® , Figure 19 ) is a targeted oral therapy designed for adults with advanced or metastatic non-small-cell lung cancer (NSCLC) that has specific MET exon 14 skipping alterations [ 85 , 86 ]. As a highly selective inhibitor, it works by blocking the MET protein, which is responsible for cancer cell growth, survival, and spread. It is especially useful for patients with this aggressive form of lung cancer as it provides a personalized, daily treatment option that has demonstrated meaningful clinical activity, often leading to tumor shrinkage in both newly diagnosed and previously treated patients [ 87 , 88 ]. Tepotinib contains a cyclic amide known as a pyridazinone (specifically 6-oxo-1,6-dihydropyridazin-3-yl), which is a 6-membered lactam ring. The pyridazinone-containing building block was introduced intact, rather than being generated de novo during the synthesis [ 80 ].

2.1.17. Voclosporin

Approved by the FDA on 22 January 2021, voclosporin ( 32 , brand name Lupkynis ® , Figure 20 ) received its first global approval for the treatment of adult patients with active lupus nephritis (LN) in combination with a background immunosuppressive therapy, typically mycophenolate mofetil and steroids [ 89 ].

Voclosporin is a novel oral calcineurin inhibitor that suppresses T-cell activation and stabilizes podocytes, thereby reducing proteinuria in lupus nephritis [ 90 ]. It is a cyclic undecapeptide (11 amino acids), produced by non-ribosomal peptide synthesis, like cyclosporine A [ 91 ]. Most residues are non-polar or unusual amino acids, which enhances membrane permeability and calcineurin binding [ 91 ]. In summary, voclosporin is a potent cyclosporine derivative, and is safer, more efficacious, and more tolerable than other calcineurin inhibitors [ 92 ]. Voclosporin is synthesized using intermediate cyclosporin A as raw material by chemical reaction [ 93 ].

2.1.18. Cabotegravir

Approved on 21 January 2021, Cabenuva ® ( Figure 21 a) is a combination of cabotegravir 33 plus rilpivirine 34 ; it is the first long-acting injectable complete regimen for HIV-1 treatment [ 94 ], given monthly or every two months for virologically suppressed adults, combining the integrase inhibitor cabotegravir with the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine to replace daily oral therapy [ 95 ]. Cabotegravir has an amide in the form of a lactam and a classic amide that connect to the halobenzyl moiety. This latter amide carbonyl next to the halobenzyl linker is devoid of metal chelation (magnesium ions at the pharmacophore). This increases the linker’s torsional flexibility, allowing it to better react to changed mutant surroundings [ 96 ]. The preparation of the secondary amide linkage is shown in Figure 21 b. This reaction shows a regioselective nucleophilic acyl substitution (amidation) converting INT29 to INT30 . The starting material INT29 contains two distinct methyl ester groups on its pyridin-4-one core: one at the C-3 position and one at the C-5 position. The primary amine, 2,4-difluorobenzylamine, selectively attacks the more electrophilic C-3 methyl ester rather than the C-5 ester. This selectivity occurs because the ester at C-3 is directly conjugated with the electron-withdrawing carbonyl group of the pyridin-4-one ring, making its carbonyl carbon highly susceptible to nucleophilic attack. Under the acidic catalysis of acetic acid, the amine displaces the methoxy leaving group to form the corresponding secondary amide, yielding INT30 with the C-5 methyl ester left completely intact [ 97 ].

2.1.19. Difelikefalin

Approved by the FDA in August 2021, difelikefalin ( 35 , brand name Korsuva ® /Kapruvia ® , Figure 22 ) is a first-in-class, peripherally restricted kappa opioid receptor agonist (KORA) approved to treat moderate-to-severe itching (pruritus) in adults with chronic kidney disease (CKD) on hemodialysis [ 98 , 99 ]. Difelikefalin is a synthetic peptide made from D-amino acids, specifically comprising D-phenylalanine (D-Phe), D-leucine (D-Leu), and D-lysine (D-Lys), along with the unnatural amino acid 4-aminopiperidine-4-carboxylic acid. The N -terminal D-phenylamine (Phe) functional group ( Figure 22 ) is a key pharmacophore, and this area is very sensitive to the binding activity of KORA [ 100 ]. The peptide backbone of the drug was efficiently assembled using EDC as the primary coupling reagent, facilitating the sequential joining of the amino acid building blocks in near-quantitative yields [ 101 ].

2.2. FDA-Approved Drugs in 2022 Containing Amide Group

In 2022, the FDA approved a total of 37 drugs, of which 22 were new chemical entities [ 28 ]. Compared with 2021, 2022 saw a decline in the number of approved chemical entities, which may partly reflect ongoing disruptions related to the COVID-19 pandemic.

While the FDA did not give a specific cause for the decline in approvals, the agency was a regular focus of criticism in 2022 for potentially moving too fast on some pharmaceuticals, especially those in the accelerated approval process [ 102 ]. The reduced number of approved drugs is correlated with a small number of small-molecule amides.

2.2.1. Futibatinib

Approved on 30 September 2022, futibatinib ( 36 , brand name Lytgobi ® , Figure 23 a) is a selective, irreversible fibroblast growth factor receptor (FGFR) inhibitor used for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements [ 103 ]. The 3,5-dimethoxybenzene structure resides in the back pocket of FGFR1, whereas the acrylamide structure forms a covalent bond with cysteine 488 [ 104 ]. The secondary amine of the pyrrolidine ring in INT31 acts as a nucleophile, selectively attacking the carbonyl carbon of acryloyl chloride via a nucleophilic acyl substitution. Triethylamine is employed as a non-nucleophilic base in chloroform to scavenge the generated hydrochloric acid byproduct and prevent protonation of the remaining starting material. The reaction selectively functionalizes the aliphatic secondary amine while leaving the less nucleophilic exocyclic aromatic amine untouched. A subsequent aqueous sodium bicarbonate wash neutralizes residual salts, cleanly furnishing the target acrylamide warhead ( Figure 23 b) [ 105 ].

2.2.2. Olutasidenib

Approved on 1 December 2022, olutasidenib ( 37 , brand name Rezlidhia ® , Figure 24 ) is an oral, small-molecule for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. It reduces the production of the oncometabolite 2-hydroxyglutarate and thereby promotes differentiation of leukemic blasts [ 106 ].

Its structure–activity relationship (SAR) is centered on a quinoline-2-one scaffold that fits into an allosteric pocket, allowing it to specifically target mutant forms while sparing wild-type IDH1 [ 107 , 108 ]. The 2-pyridone-containing building block was introduced intact rather than being generated de novo during the synthesis [ 109 ].

2.2.3. Adagrasib

Approved on 12 December 2022, adagrasib ( 38 , brand name Krazati ® , Figure 25 a) is a small molecule for the treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC harboring a KRAS G12C mutation who have received at least one prior systemic therapy [ 110 ]. Adagrasib is an orally bioavailable, covalent small-molecule inhibitor that selectively targets the KRAS G12C mutant protein by irreversibly binding to the cysteine residue at position 12, locking KRAS in its inactive GDP-bound state and thereby inhibiting downstream oncogenic signaling through pathways such as MAPK and PI3K [ 111 ]. The secondary amine on the piperazine ring of intermediate ( INT32 ) acts as a nucleophile, attacking the activated carbonyl center of sodium 2-fluoroacrylate. Potassium carbonate serves as a mild base to facilitate the coupling reaction. This nucleophilic substitution cleanly installs the electrophilic 2-fluoroacrylamide warhead onto the piperazine nitrogen while leaving the other tertiary amine centers intact [ 112 ].

2.2.4. Deucravacitinib

Approved on 9 September 2022, deucravacitinib ( 39 , brand name: Sotyktu ® , Figure 26 a) is a first-in-class, oral medication that represents a major leap forward in treating autoimmune diseases [ 113 ]. It is a first-in-class, oral, selective allosteric inhibitor of tyrosine kinase 2 (TYK2), a member of the JAK family, approved for moderate-to-severe plaque psoriasis [ 114 ]. The inclusion of deuterium strengthens chemical bonds, which reduces metabolic degradation and potentially allows for lower or less frequent dosing while maintaining efficacy [ 115 , 116 ]. The cyclopropyl amide in deucravacitinib is a masterclass in molecular engineering. It is a multifunctional group that is essential for the drug’s high potency and exceptional selectivity to limit hERG liability [ 117 ].

The final step in the preparation of deucravacitinib is shown in Figure 26 b. The reaction cross-couples the primary cyclopropanecarboxamide reagent with the electrophilic C-6 carbon of the pyridazine core ( INT33 ), displacing the chlorine atom. This C–N bond formation is driven by a catalytic system comprising tris(dibenzylideneacetone)dipalladium(0) and the bidentate phosphine ligand dppf, which facilitate oxidative addition and reductive elimination cycles. Potassium phosphate acts as the base to deprotonate the amide in 1,4-dioxane at 85 °C, efficiently introducing the cyclopropyl amide group without disturbing the existing deuterated amide framework [ 105 ].

2.2.5. Mitapivat

Approved on 17 February 2022, mitapivat ( 40 , brand names Pyrukynd ® and Aqvesme ® , Figure 27 a) is a first-in-class oral pyruvate kinase activator that treats hemolytic anemia in adults with pyruvate kinase (PK) deficiency. It works by increasing PK activity to boost red blood cell health. It is also approved for treating anemia in adults with alpha- or beta-thalassemia [ 118 ]. It features a quinoline-8-sulfonamide core, a central phenyl ring, and a cyclopropylmethylpiperazine moiety. This reaction outlines a CDI-mediated amide coupling to synthesize mitapivat from carboxylic acid. 1,1′-Carbonyldiimidazole (CDI) first activates the carboxylic acid group of intermediate ( INT34 ) by converting it into a reactive acyl imidazole intermediate. The free secondary amine of the piperazine dihydrochloride salt then undergoes nucleophilic acyl substitution at this activated carbonyl center. Operating in N , N -dimethylacetamide (DMA) at room temperature for 4 h, this protocol cleanly couples the fragments to generate the central amide linkage of the drug while leaving the sulfonamide and quinoline functionalities completely unaffected ( Figure 27 b) [ 105 ].

2.2.6. Lutetium Lu 177 Vipivotide Tetraxetan

Approved on 23 March 2022, lutetium Lu 177 vipivotide tetraxetan ( 41 , brand name Pluvicto ® , Figure 28 ) is an FDA-approved, targeted radioligand therapy for adult patients with advanced, PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) previously treated with chemotherapy and hormone therapy. It works by delivering radiation directly to cancer cells, significantly extending survival and reducing tumor size, with common side effects including fatigue, dry mouth, and nausea. Its structure is composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium, 177 Lu [ 119 ]. The synthesis of lutetium Lu 177 vipivotide tetraxetan is achieved via multi-step coupling mediated by O-(Benzotriazol-1-yl)-N,N,N’,N’-bis (tetramethylene)uronium Hexafluorophosphate (HBTU) and DIPEA as a base [ 105 ].

2.2.7. Terlipressin

Approved on 14 September 2022, terlipressin ( 42 , brand name Terlivaz ® , Figure 29 ) was approved by the U.S. Food and Drug Administration for improving kidney function in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function, a life-threatening complication of advanced liver disease [ 120 ]. It is an analog of vasopressin, and it acts by causing vasoconstriction of the splanchnic vasculature [ 121 ]. Its core structure consists of a nine-amino acid peptide chain that is cyclized by a disulfide bond between two cysteine residues, a hallmark feature shared with vasopressin analogs [ 122 ]. The synthesis of terlipressin is achieved via multi-step coupling mediated by N -Hydroxy-5-norbornene-2,3-dicarboximide (HONB) and DCC [ 123 ].

2.3. FDA-Approved Drugs in 2023 Containing Amide Group

In 2023, the FDA approved a total of 55 drugs, of which 38 were new chemical entities [ 28 ]. As such, 2023 was a very good year for drug discovery, especially for small-molecule innovation and clinically meaningful advances. It reflects a mature, productive ecosystem rather than a sudden breakthrough era, but it is a clear signal that modern drug discovery is delivering at scale.

2.3.1. Nirogacestat

Approved on 27 November 2023, nirogacestat ( 43 , brand name Ogsiveo ® , Figure 30 a) is an orally available, small-molecule gamma-secretase inhibitor developed for the treatment of adults with progressing desmoid tumors, a rare and locally aggressive soft-tissue neoplasm. By inhibiting gamma-secretase, nirogacestat suppresses Notch signaling, a key pathway implicated in the growth and survival of desmoid tumor cells [ 124 , 125 ]. FDA approval was based on the phase 3 DeFi trial, which demonstrated significant improvements in progression-free survival, tumor response, and patient-reported outcomes compared with placebo, establishing nirogacestat as the first approved systemic therapy specifically for this disease [ 125 , 126 ]. Chemically, it is an imidazole-based drug containing an amide group. The final step for the synthesis of nirogacestat is performed under 2-(2-Pyridon-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TPTU) and DIPEA as a base, with the carboxylic acid ( INT35 ) as starting material ( Figure 30 b) [ 127 ].

2.3.2. Capivasertib

Approved by the U.S. FDA on 16 November 2023, capivasertib ( 44 , brand name Truqap ® , Figure 31 a) is a small molecule that, in combination with fulvestrant, has an indication for adult patients with advanced or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer that has specific genetic alterations (PIK3CA, AKT1, or PTEN) [ 128 ]. Capivasertib can effectively inhibit the AKT pathway, leading to dephosphorylation of key downstream targets [ 129 ]. Fulvestrant serves as the foundational hormonal therapy designed to stop hormone receptor-positive breast cancer cells from growing by inhibiting estrogen action [ 130 ]. The formation of the amide bond in capivasertib is shown in Figure 31 b. The transformation relies on HATU as the coupling reagent to convert the carboxylic acid ( INT36 ) into a highly reactive activated ester that ultimately is converted to amide ( INT37 ). DIPEA serves as the non-nucleophilic base to scavenge acid, while DMA (dimethylacetamide) provides a polar, aprotic solvent environment to keep all components dissolved at 20 °C [ 129 ].

2.3.3. Repotrectinib

Approved on 15 November 2023, repotrectinib ( 45 , brand name Augtyro ® , Figure 32 a) is a next-generation tyrosine kinase inhibitor (TKI) approved by the FDA for treating specific types of advanced cancer driven by genetic alterations [ 131 ]; traditional approval was granted for adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). This was the first approval to specifically include patients previously treated with a ROS1 TKI [ 132 ]. The first-generation TRK inhibitors’ acquired resistance can be addressed by using the macrocyclization approach, which makes the inhibitor’s molecular structure more compact [ 133 ]. Repotrectinib is obtained via using pentafluorophenyl diphenylphosphinate (FDPP) as peptide coupling starting from intermediate ( INT38 ) [ 134 ].

2.3.4. Fruquintinib

Approved on 8 November 2023, fruquintinib ( 46 , brand name Fruzaqla ® , Figure 33 ) is an oral, selective inhibitor of vascular endothelial growth factor receptors for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy [ 135 , 136 ]. Its main pharmacological use is in refractory metastatic colorectal cancer, where it improves survival compared with placebo by inhibiting the VEGF pathway that tumors use to grow new blood vessels [ 137 ]. Beyond its approved CRC use, fruquintinib continues to be studied in other cancer indications [ 138 , 139 ]. The H-bond-rich region was engaged by an amide group forming H-bonds with specific amino acids (glutamic acid and aspartic acid) in the binding pocket [ 140 ]. The secondary amide building block was introduced intact rather than being generated de novo during the synthesis [ 141 ].

2.3.5. Momelotinib

Approved on 15 September 2023, momelotinib ( 47 , brand name Ojjaara ® , Figure 34 a) is an oral kinase inhibitor targeting Janus kinase 1/2 (JAK1), JAK2 for the treatment of adult patients with intermediate- or high-risk myelofibrosis who have anemia [ 142 ]. Its unique combination of activities helps reduce constitutional symptoms, address splenomegaly (enlarged spleen), and decrease hepcidin levels to alleviate anemia in people with myelofibrosis [ 143 ]. This indication fills an important gap in managing myelofibrosis with anemia, a condition marked by bone marrow dysfunction, low blood counts, fatigue, and other disease-related symptoms [ 144 ]. The last step for preparing momelotinib is shown in Figure 34 b. The transformation utilizes INT39 , aminoacetonitrile, EDC as the carbodiimide activating agent, and HOBt as a racemization-suppressing additive to generate a reactive active ester. TEA acts as the base to deprotonate the amine, and DMF serves as the polar aprotic solvent [ 129 ].

2.3.6. Lotilaner

Approved on 25 July 2023, lotilaner ( 48 , brand name Xdemvy ® , Figure 35 a) is an isoxazoline-class antiparasitic drug used to kill parasites such as mites, fleas, and ticks. It is available in both human and veterinary formulations [ 145 , 146 ]. Lotilaner works by targeting parasite chloride channels, leading to the paralysis and death of mites, fleas, and ticks. In veterinary use, isoxazolines can occasionally cause neurologic adverse reactions, such as tremors, ataxia, or seizures, so careful dosing and veterinary supervision are recommended [ 147 , 148 ]. The amide bonds are introduced in lotilaner via the HBTU coupling reagent starting from intermediate INT40 ( Figure 35 b). Lotilaner ( 48 ) is generated by efficient amide bond formation while fully preserving the halogenated groups and stereochemical configuration [ 127 ].

2.3.7. Ritlecitinib

Approved on 23 June 2023, ritlecitinib ( 49 , brand name LITFULO ® , Figure 36 a) is for the treatment of severe alopecia areata in adults and adolescents aged 12 years and older [ 149 ]. It is taken orally once daily. This approval marked ritlecitinib as the first treatment specifically indicated for adolescents with this condition and the second JAK inhibitor (the first was baricitinib [ 150 ]) that was overall approved for alopecia areata in the U.S [ 151 ]. Chemically, it contains an acrylamide moiety ( Figure 36 b) whose installation is mediated by acryloyl chloride on INT41 and DIPEA in THF [ 152 ].

2.3.8. Nirmatrelvir and Ritonavir

Approved on 25 May 2023, the combination of nirmatrelvir 50 plus ritonavir 51 (Paxlovid ® ) was among the first oral antivirals shown to significantly reduce hospitalization and death in high-risk COVID-19 patients [ 153 , 154 ]. Nirmatrelvir ( Figure 37 ) is an oral antiviral protease inhibitor that targets the SARS-CoV-2 main protease (Mpro, also called 3CLpro) [ 155 ]. By inhibiting this viral cysteine protease, nirmatrelvir prevents viral polyprotein cleavage, which is essential for viral replication, thereby stopping the virus from multiplying in infected cells [ 156 ]. According to the structural analysis, Nirmatrelvir’s chemical structure is regarded as a peptidomimetic made up of two primary fragments, known as the “western fragment” and “eastern fragment,” connected by an amide bond. The eastern segment is a γ-lactam analog of Gln with the terminal electrophilic warhead, whereas the western fragment is a bicyclic proline residue linked to an L -tert-leucine capped with a trifluoroacetyl group [ 157 ]. Ritonavir is an HIV protease inhibitor originally developed for antiretroviral therapy. In the Paxlovid combination, its primary role is pharmacokinetic boosting rather than direct antiviral activity. Ritonavir inhibits CYP3A4, the liver enzyme responsible for metabolizing nirmatrelvir, thereby increasing nirmatrelvir plasma concentrations and prolonging its activity [ 158 , 159 ]. Technically, ritonavir can be described as an L-valinamide derivative where the alpha-amino group is acylated. The synthetic route used for the first kilogram-scale manufacture of nirmatrelvir utilizes HATU/DIPEA and EDC as coupling reagents [ 160 ]. The synthesis of ritonavir fundamentally relies on a convergent synthetic strategy. The process constructs a C2-symmetric-like core diamino alcohol backbone, which is subsequently modified with two distinct heterocyclic thiazole arms via carbamate and amide couplings [ 161 ].

2.3.9. Fezolinetant

Approved on 12 May 2023, fezolinetant ( 52 , brand name Veozah ® , Figure 38 a) is a novel, non-hormonal prescription medication approved to treat moderate-to-severe vasomotor symptoms (hot flashes and night sweats) associated with menopause. It acts as a neurokinin 3 (NK3) receptor antagonist, targeting the brain’s thermoregulatory center to reduce the frequency and severity of hot flashes [ 162 , 163 ]. It contains a triazolopiperazine scaffold endowed with an amide functional group. The tertiary amide is formed via acylation of INT42 with 4-fluorobenzoyl chloride to give INT43, accompanied by simultaneous deprotection of the dimethoxybenzyl group, in excellent yield (95%) [ 164 ].

2.3.10. Zavegepant

Approved on 10 March 2023, zavegepant ( 53 , brand name Zavzpret ® , Figure 39 a) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist for the acute treatment of migraine with or without aura in adults [ 165 , 166 ]. Zavegepant does not carry a boxed warning, recommend routine pretreatment or special monitoring, or require a Risk Evaluation and Mitigation Strategy program [ 166 ]. It contains a lactam and a classic amide moiety. The synthesis of the urea intermediate for the preparation of zavegepant is presented in Figure 39 b. This reaction demonstrates the use of N , N ’-disuccinimidyl carbonate (DSC) as a coupling reagent to form an asymmetric urea bond. The DSC activates either the secondary amine of the piperidine hydrochloride salt ( INT44 ) or the primary amine of the phenylalanine-derived indazole ester, allowing them to couple efficiently in THF. This reaction successfully links the two complex building blocks together to yield the urea product INT45 in a high yield of 78% [ 127 ].

2.3.11. Omaveloxolone

Approved on 28 February 2023, omaveloxolone ( 54 , brand name Skyclarys ® , Figure 40 a) is a landmark medication, primarily recognized as the first and only drug approved to treat Friedreich’s Ataxia (FA) [ 167 , 168 ]. It serves as a potent activator of the NRF2 pathway, which is critical for restoring mitochondrial function and reducing the oxidative stress that characterizes this rare, progressive genetic disorder [ 169 ]. It is an oleanane triterpenoid; it has some structural similarities to steroids with some differences (both C3 and C28 are highly unreactive to substitution reactions) [ 170 ]. The synthesis ( Figure 40 b) utilizes 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) as a coupling reagent to facilitate the amide bond formation between the sterically hindered primary amine of INT46 and 2,2-difluoropropionic acid. CDMT activates the carboxylic acid in 2-Me-THF to allow efficient acylation at the complex, multi-cyclic core’s amine position. This direct coupling successfully completes the late-stage synthesis of the therapeutic drug omaveloxolone ( 54 ) [ 170 ].

2.3.12. Daprodustat

Approved by the U.S. Food and Drug Administration (FDA) in February 2023, daprodustat ( 55 , brand name Jesduvroq ® , Figure 41 ) is a once-daily oral medication for treating anemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for at least four months. It is the first oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI) approved in the U.S. [ 171 ]. It is characterized as a barbituric acid core substituted by two cyclohexyl groups and a glycine-derived side chain. Daprodustat’s solubility is governed by the need to balance the solvation of its polar glycine-carboxylic acid arm with its large, hydrophobic dicyclohexyl-barbiturate core. The chemical synthesis of daprodustat focuses on constructing its core barbituric acid derivative structure and coupling it with a glycine moiety [ 172 ].

2.3.13. Pirtobrutinib

Approved on 27 January 2023, pirtobrutinib ( 56 , brand name Jaypirca ® , Figure 42 a) is a small molecule for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior systemic therapies that include a BTK inhibitor [ 173 , 174 ]. This approval was based on response rates observed in clinical trials rather than long-term outcomes. Unlike covalent inhibitors that bind to the Cys481 residue in the ATP-binding pocket, pirtobrutinib interacts with other residues, allowing it to inhibit BTK even when C481 is mutated [ 175 ]. Pirtobrutinib is a large, aromatic, heterocycle-rich small molecule with multiple heteroatoms (N, O), several aromatic rings, and limited ionizable functionality under neutral conditions. The last-stage modification ( Figure 42 b) features the acid-catalyzed partial hydrolysis of the nitrile group on INT47 using methanesulfonic acid and water. The reaction converts the electron-deficient nitrile directly into a primary amide functionality without disrupting the sensitive pyrazole or benzoxazinone rings. Subsequent neutralization with ammonium hydroxide delivers the targeted BTK inhibitor pirtobrutinib ( 56 ) in an excellent 84% yield [ 127 ].

2.3.14. Trofinetide

Approved on 10 March 2023, trofinetide ( 57 , brand name Daybue ® , Figure 43 ) is a novel synthetic analog of the naturally occurring tripeptide glycine-proline-glutamate (GPE) designed to address the neurodevelopmental disorder Rett syndrome [ 176 , 177 ]. It modulates neuronal function and is believed to improve synaptic activity and reduce neuroinflammation, although its precise mechanism is not fully understood [ 178 ]. Trofinetide is administered orally and is indicated for the treatment of Rett syndrome in both adult and pediatric patients aged 2 years and older [ 179 ]. Trofinetide (H-Gly-L-2-MePro-L-Glu-OH) is a synthetic tripeptide analog of glypromate. Its synthesis can be completed using three primary synthetic approaches: Liquid-Phase Peptide Synthesis (LPPS), Solid-Phase Peptide Synthesis (SPPS), and Silylation-Assisted Bulk Synthesis. The primary structural hurdle is coupling the sterically hindered, non-natural amino acid L-2-methylproline (2-MePro) to L-glutamic acid and glycine [ 180 ].

2.3.15. Rezafungin

Approved on 22 March 2023, rezafungin ( 58 , brand name Rezzayo ® , Figure 44 ) is a next-generation echinocandin antifungal medication developed for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options [ 181 ]. It works by inhibiting 1,3-β-D-glucan synthase, an enzyme essential for fungal cell wall synthesis, weakening the fungal cell wall and restricting fungal growth and spread [ 182 , 183 ]. Unlike many older echinocandins, rezafungin’s chemical and pharmacokinetic properties support once-weekly intravenous dosing, which can simplify therapy compared to daily regimens [ 184 ]. It is a cyclic hexapeptide echinocandin antifungal analog of anidulafungin, characterized by a unique choline aminal ether moiety at the C5 ornithine position. It is a semi-synthetic drug. Its production relies on a hybrid process: the massive, highly complex cyclic peptide core is generated biologically via fungal fermentation, while the structural modifications that give the drug its long-acting stability are added via chemical synthesis [ 185 ].

2.4. FDA-Approved Drugs in 2024 Containing Amide Group

In 2024, the FDA approved a total of 50 drugs, of which 34 were new chemical entities [ 28 ]. As such, 2024 has been an interesting year from the viewpoint of a medicinal chemist, with the approval of two deuterated medications; this class of chemicals now has four approvals overall [ 28 ]. Moreover, N -aromatic heterocycles and fluorine atoms are present in two-thirds of all the small molecules approved in the year [ 28 ].

2.4.1. Alyftrek ®

The FDA approved Vertex Pharmaceuticals’ Alyftrek ® (vanzacaftor 59 /tezacaftor 60 /deutivacaftor 61 , Figure 45 ) on 20 December 2024, for treating cystic fibrosis in patients aged 6 and older with at least one F508del mutation or other responsive mutations [ 186 ]. This once-daily, next-in-class triple-combination modulator offers a new, effective treatment option to enhance lung function. Vanzacaftor is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector that improves folding and trafficking of the defective CFTR protein to the cell surface in cystic fibrosis. It is designed to act synergistically with other CFTR modulators to enhance functional CFTR expression [ 187 , 188 , 189 ]. Tezacaftor is a CFTR corrector that increases the amount of properly processed CFTR protein delivered to the cell membrane, particularly in patients with the F508del mutation. It is commonly used in combination regimens to improve chloride transport [ 190 , 191 ]. Deutivacaftor is a deuterated CFTR potentiator that enhances the opening probability of CFTR channels at the cell surface while offering improved pharmacokinetics and a longer duration of action compared with ivacaftor. It helps sustain CFTR activity when used alongside CFTR correctors [ 190 ]. The synthesis of tezacaftor concludes with a critical amide bond coupling that joins the cyclopropanecarboxylic acid core to the aminoindole fragment [ 192 , 193 ]. The synthesis of deutivacaftor is accomplished by a convergent amide coupling between an unlabelled quinoline core fragment and a highly deuterated (d 9 ) aminophenol core fragment [ 194 ].

2.4.2. Ensartinib

Approved on 18 December 2024, ensartinib ( 62 , brand name Ensacove ® , Figure 46 a) is a next-generation oral tyrosine kinase inhibitor (TKI) approved by the FDA for the treatment of ALK-positive non-small-cell lung cancer [ 195 ]. It is specifically indicated for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor [ 196 ]. ESB’s chemical structure contains a dichloro-fluorophenyl ring and cyclic tertiary amine rings (piperazine). Ensartinib’s solubility is primarily driven by its large, hydrophobic heterocyclic structure. As per the synthesis ( Figure 46 b), the carboxylic acid of INT48 is coupled with the primary aniline amine of the coregent using the popular peptide coupling reagents HATU and DIPEA in DMF at 20 °C to yield an amide bond on INT49 in an excellent 83% yield [ 194 ].

2.4.3. Iomeprol

Approved on 27 November 2024, iomeprol ( 63 , brand name Iomervu ® , Figure 47 a) is a nonionic, iodinated radiographic contrast agent for intra-arterial and intravenous procedures in both adult and pediatric patients [ 197 ]. Developed by Bracco Diagnostics Inc., it is used to enhance visualization during various diagnostic imaging procedures, including CT scans and arteriography [ 198 ]. At the 1 and 3 positions, there are two carbamoyl groups (amide side chains) substituted with 2,3-dihydroxypropyl groups. As per the synthesis ( Figure 47 b) [ 199 ], the dicarboxylic acid INT50 is treated with thionyl chloride to convert both carboxylic acid groups into highly reactive acyl chlorides, yielding INT51 . Next, the relatively hindered secondary aniline nitrogen is selectively acylated using chloroacetyl chloride to introduce the chloroacetamide arm in INT52 . Finally, addition of the aminodiol nucleophile results in chemoselective amidation at the two aromatic acyl chloride positions, leaving the alkyl chloride untouched to yield the highly hydrophilic, iodinated target intermediate INT53 .

2.4.4. Revumenib

Approved on 15 November 2024, revumenib ( 64 , brand name Revuforj ® , Figure 48 a) is a first-in-class, oral menin inhibitor approved by the FDA for the treatment of specific, difficult-to-treat types of acute leukemia [ 200 , 201 ]. It works by blocking the interaction between the menin protein and KMT2A, reducing leukemogenic gene expression [ 202 ]. It is a complex multi-ring system, including a diazaspiro [3.5]nonane core and a sulfonamide group. The synthesis ( Figure 48 b) involves the carboxylic acid group of INT54 being converted into a highly reactive acyl chloride intermediate using oxalyl chloride in dichloromethane (DCM) at 0 °C. In the subsequent step, the secondary amine N -ethylisopropylamine is introduced to attack this activated electrophilic intermediate, successfully yielding the tertiary amide INT55 [ 203 ].

2.4.5. Sulopenem Etzadroxil

Sulopenem etzadroxil 65 /probenecid 66 , marketed as Orlynvah ® ( Figure 49 a), is an oral fixed-dose antibiotic combination that the U.S. Food and Drug Administration approved on 25 October 2024 for the treatment of uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options [ 204 , 205 ]. It combines the pro-drug sulopenem etzadroxil (a broad-spectrum penem antibacterial) with probenecid (which increases sulopenem systemic exposure by inhibiting renal tubular secretion) [ 206 ]. Sulopenem is a thiopenem, characterized by a sulfur atom in the five-membered ring adjacent to the beta-lactam ring. 65 (the prodrug form of sulopenem) is created by joining an etzadroxil group (ethyl 2-ethylbutanoate) to the carboxylic acid at the C2 position [ 207 ]. The synthesis ( Figure 49 b) proceeds via starting material INT56, which contains an unstable trithiocarbonate group attached to the beta-lactam ring. When treated with triethyl phosphite, the trivalent phosphorus nucleophilically attacks the thiocarbonyl sulfur atom. This leads to the extrusion of the central sulfur atom as a phosphite sulfide byproduct, effectively converting the trithiocarbonate group into a transient, highly reactive sulfur-stabilized carbanion or ylide intermediate. This reactive carbon center then immediately attacks the neighboring oxalyl carbonyl group attached to the nitrogen atom, closing the five-membered ring. This tandem sulfur-abstraction and intramolecular cyclization sequence is a classic methodology used in the synthesis of advanced beta-lactam antibiotics, successfully generating the penem core structure found in INT57 [ 208 ].

2.4.6. Inavolisib

Approved in October 2024, inavolisib ( 66 , brand name Itovebi ® , Figure 50 a) is a first-in-class targeted therapy used to treat specific types of advanced breast cancer. It is primarily prescribed for adults with HR-positive, HER2-negative breast cancer that has a PIK3CA mutation [ 209 ]. In inavolisib, a carbamate links part of the heterocyclic system (via an oxygen) to a nitrogen-containing moiety. Structurally, it sits within the oxazolidinone-related region of the molecule. It features a primary amide group on the eastern side of the molecule. Inavolisib is neutral and amphiphilic; the synthesis ( Figure 50 b) involves [ 210 ] the nucleophilic displacement of the aryl bromide on INT58 with the primary amine of L-alanine. Following this successful amination, the resulting free carboxylic acid tether is immediately engaged in a second-step peptide coupling. The activating agent HATU, alongside an ammonium chloride source, converts the carboxylic acid into a primary amide, completing the installation of the amino acid side chain to deliver inavolisib (66) in a 46% yield over the sequence.

2.4.7. Levacetylleucine

Approved on 24 September 2024, levacetylleucine ( 67 , brand name Aqneursa ® , Figure 51 a) is also known as N -acetyl- L -leucine. It is a small-molecule, modified amino acid developed for the treatment of neurological symptoms associated with Niemann–Pick disease type C (NPC), a rare, inherited neurodegenerative disorder [ 211 ]. It is the pharmacologically active L-enantiomer of acetylleucine and is administered orally, typically as a suspension [ 212 ]. Although its precise mechanism of action is not fully defined, levacetylleucine is thought to improve neuronal function by modulating cellular energy metabolism and stabilizing neuronal signaling, leading to improvements in gait, coordination, and other neurological manifestations seen in NPC [ 213 ]. The primary amine of L-leucine benzyl ester ( INT59 ) is acetylated by reacting directly with acetic acid. Typically, simple carboxylic acids like acetic acid require heating or harsher conditions to form amides with amines, but the addition of the potent peptide coupling reagent HATU along with the non-nucleophilic base DIPEA efficiently activates the acetic acid in situ. This allows the amine to nucleophilically attack the activated acyl intermediate smoothly at mild temperatures, yielding the protected, acetylated amino acid product INT60 [ 194 ].

2.4.8. Lazertinib

Approved on 19 August 2024, lazertinib ( 68 , brand name Lazcluze ® , Figure 52 a) is a targeted cancer therapy, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) [ 214 ]. It blocks EGFR signaling in cancer cells, slowing their growth and survival [ 214 ]. It is designed to penetrate the brain and target common EGFR mutations seen in non-small-cell lung cancer (NSCLC) [ 215 ]. Its structure reflects classic kinase-inhibitor design principles, featuring a heteroaromatic core that fits into the ATP-binding pocket of EGFR, substituents that enhance mutant selectivity and binding affinity. It features a substituted pyrazole core, crucial for selectivity and binding [ 216 ], with a phenyl group at R1 and a morpholine-containing side chain for improved pharmacokinetics [ 216 ]. It contains an acrylamide functional group that acts as a covalent warhead. As per the synthesis [ 217 ], under basic conditions using triethylamine (TEA), the 4-chlorobutanamide side chain of INT61 undergoes a base-mediated elimination of hydrochloric acid (HCl) to install the terminal alkene, yielding the characteristic acrylamide (Michael acceptor) warhead found in lazertinib.

2.4.9. Tovorafenib

Approved on 23 April 2024, tovorafenib ( 69 , brand name Ojemda ® , Figure 53 ) is an oral, once-weekly, type II RAF kinase inhibitor developed for the treatment of pediatric brain tumors driven by alterations in the MAPK signaling pathway [ 218 , 219 ]. It targets both mutant and wild-type RAF kinases, including BRAF V600 mutations, as well as BRAF fusions and rearrangements, helping to suppress tumor growth in BRAF-altered cancers [ 220 ]. Tovorafenib is indicated for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring these BRAF alterations [ 219 ]. Unlike covalent inhibitors, tovorafenib does not contain a reactive warhead such as an acrylamide; instead, it relies on high-affinity, reversible binding driven by hydrogen bonding, π–π interactions, and hydrophobic contacts. However, the thiazole amide is an important structural feature that contributes to both binding and drug-like properties. The compound has moderate polarity with heteroatoms (for example, amide, thiazole, aromatic systems) but limited hydrogen-bond donation. The amide bonds in tovorafenib are generated via oxalyl chloride and the EDC/HOBt coupling reagent [ 221 ].

2.4.10. Ceftobiprole Medocaril Sodium

Approved on 3 April 2024, ceftobiprole medocaril sodium ( 70 , brand name Zevtera ® , Figure 54 ) is a fifth-generation cephalosporin antibiotic developed as the prodrug of ceftobiprole, designed for intravenous use and active against a broad spectrum of Gram-positive and some Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) [ 222 ]. It works by binding to multiple penicillin-binding proteins (PBPs), inhibiting bacterial cell wall synthesis, and exerting rapid bactericidal activity against susceptible pathogens [ 223 , 224 ]. The medocaril moiety improves water solubility and prodrug delivery, with conversion in vivo to the active antibiotic ceftobiprole [ 225 ]. Its core structure is the characteristic cephalosporin nucleus, which consists of a four-membered β-lactam ring fused to a six-membered dihydrothiazine ring. This bicyclic scaffold is essential for antibacterial activity, as it enables binding to bacterial penicillin-binding proteins (PBPs) and inhibition of cell wall synthesis once the active drug is released.

2.4.11. Danicopan

Approved on 29 March 2024, danicopan ( 71 , brand name Voydeya ® , Figure 55 a) is an add-on treatment to C5 inhibitors for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have persistent extravascular hemolysis. It is an oral complement factor D inhibitor designed to improve hemoglobin levels in patients inadequately controlled on standard C5 inhibitor therapy [ 226 ]. The (2-methylpyrimidin-5-yl) group at the 5-position of the indazolyl moiety gives a biheteroaryl framework. This group imparts improved potency to danicopan when compared with the unsubstituted analog [ 227 ]. Synthetically, the carboxylic acid of the indazole intermediate INT62 is coupled with the secondary amine of the fluoropyrrolidine core using the peptide coupling reagent HATU and the non-nucleophilic base DIPEA, constructing the central amide bond with an excellent 96% yield ( Figure 55 b) [ 227 ].

2.4.12. Vadadustat

Approved in March 2024, vadadustat ( 72 , brand name Vafseo ® , Figure 56 a) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor used to treat anemia due to chronic kidney disease (CKD) in adults who have been on dialysis for at least three months [ 228 ]. It works by stabilizing HIF to increase the body’s production of erythropoietin and promote red blood cell formation. Vadadustat binds the catalytic site of PHD2, resulting in bidentate chelation interactions with the active site Fe atom, a salt bridge interaction with Arg383 deep in the binding pocket, an H-bond interaction of the vadadustat phenolic OH with Tyr303, and nonspecific lipophilic interactions of the chlorophenyl ring with residues near the HIF binding site [ 229 ]. The carboxylic acid of the pyridine intermediate INT63 is coupled with the amine of the glycine core using the peptide coupling reagent EDC and the non-nucleophilic base DIPEA, constructing the central amide bond of INT64 with an excellent 40% yield ( Figure 56 b) [ 230 ].

2.4.13. Resmetirom

Approved in March 2024, resmetirom ( 73 , brand name Rezdiffra ® , Figure 57 ) is an oral, liver-directed thyroid hormone receptor-β agonist for adults with noncirrhotic nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), with moderate to advanced fibrosis (F2–F3), to be used alongside diet and exercise [ 231 , 232 ]. It is the first FDA-approved medication specifically indicated for NASH/MASH with fibrosis. Resmetirom works by selectively activating THR-β in the liver, reducing hepatic fat accumulation, inflammation, and fibrosis progression [ 233 ]. Chemically, it is a non-steroidal, triiodothyronine (T3)-mimetic derivative, designed to retain the lipid-lowering and metabolic effects of thyroid hormone in the liver while reducing systemic exposure [ 234 ]. It can be synthesized via an optimized, highly efficient four-step streamlined process. This route replaces older, lengthier patent processes by utilizing a clever “one-pot” tandem cyclization and hydrolysis sequence, achieving an overall yield of 44.3% and a purity of 98.8% [ 235 ].

2.4.14. Cefepime/Enmetazobactam

Cefepime 74 /enmetazobactam 75 , marketed under the brand name Exblifep ® ( Figure 58 ), was approved by the FDA in February 2024. The product was developed by Allecra Therapeutics and is indicated for the treatment of complicated urinary tract infections, including pyelonephritis, in adults and certain pediatric patients caused by susceptible Gram-negative microorganisms [ 236 ]. Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis. Enmetazobactam is a novel β-lactamase inhibitor that protects cefepime from degradation by certain β-lactamases, including extended-spectrum β-lactamases (ESBLs) [ 237 ]. The combination restores and enhances activity against resistant Enterobacterales, offering an important therapeutic option in settings where antimicrobial resistance is a concern [ 238 ]. The FDA approval was supported by results from a Phase 3, randomized, double-blind clinical trial comparing cefepime/enmetazobactam with piperacillin/tazobactam in patients with complicated urinary tract infections. The study demonstrated statistical superiority in overall treatment success and higher microbiological eradication rates, with a safety profile generally consistent with other β-lactam antibiotics [ 239 ]. The drug is administered intravenously, and dose adjustments are required in patients with renal impairment [ 240 ]. Common adverse reactions include infusion site reactions, gastrointestinal symptoms such as diarrhea and nausea, headache, and potential hypersensitivity reactions typical of β-lactam antibiotics [ 241 ]. Overall, cefepime/enmetazobactam represents a significant addition to the antimicrobial armamentarium, particularly for infections caused by ESBL-producing Gram-negative bacteria, and may help reduce reliance on carbapenem therapy in appropriate patients [ 242 ]. Cefepime is derived from the cephalosporin nucleus, 7-aminocephalosporanic acid. Chemically, it contains the characteristic β-lactam ring fused to a dihydrothiazine ring that defines cephalosporins. Enmetazobactam is a β-lactamase inhibitor structurally related to tazobactam but modified to improve potency and spectrum. While both are penicillanic acid sulfones (PAS), the structural difference lies in the addition of a methyl group to the triazole moiety of enmetazobactam. For the synthesis of cefepime, 7-amino-3-(l-methylpyrrolidinio)methyl-3-cephem-4-carboxylate is used, which reacts with the activated ester [ 243 ].

2.5. FDA-Approved Drugs in 2025 Containing Amide Group

In 2025, the FDA approved a total of 46 drugs, of which 34 were new chemical entities [ 244 ]. Kinase inhibitors are making steady inroads into inflammatory and immune-mediated diseases, with therapies targeting Bruton’s tyrosine kinase (BTK) at the forefront. Initially approved to treat blood cancers by eliminating malignant B cells, BTK inhibitors are now being leveraged for their ability to fine-tune B-cell activity in autoimmune conditions. This year marked key milestones for the class. Sanofi secured the first approval for its BTK inhibitor rilzabrutinib ( 76 ), marketed as Wayrilz ® , to treat immune thrombocytopenia, a rare autoimmune blood disorder [ 245 ]. Meanwhile, Novartis won regulatory clearance for remibrutinib ( 77 ), sold as Rhapsido ® , for chronic spontaneous urticaria, commonly known as chronic hives [ 246 ]. Both drugs contain an amide linker in their skeleton.

2.5.1. Rilzabrutinib

Approved on 29 August 2025, rilzabrutinib ( 76 , brand name Wayrilz ® , Figure 59 a) is an oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor developed by Sanofi for the treatment of immune-mediated diseases [ 247 ]. It works by modulating B-cell and other immune signaling pathways involved in autoimmune disorders [ 248 ]. Before approval, rilzabrutinib was granted Fast Track designation in 2020 for immune thrombocytopenia (ITP), followed in 2025 by orphan drug designations for warm autoimmune hemolytic anemia (wAIHA), IgG4-related disease, and sickle cell disease [ 249 ]. In February 2026, it also received Breakthrough Therapy designation for wAIHA, reflecting evidence of potential substantial improvement over existing treatments. Rilzabrutinib continues to be studied in additional rare and immune-mediated conditions [ 250 ]. Chemically, it is designed as a targeted kinase inhibitor with a structure optimized to bind selectively to the ATP-binding site of BTK. Unlike earlier covalent BTK inhibitors, rilzabrutinib forms a reversible covalent bond with a cysteine residue (Cys481) in the BTK active site, allowing strong target engagement with controlled off-target activity [ 251 , 252 ]. It displays a cyanoacrylamide warhead ( Figure 59 a). Synthetically, the free piperidine group from INT65 was condensed with cyanoacetic acid using hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU) and TEA in DMF to give amide INT66 (two-step yield: 32%). Eventually, the crucial step to form α-cyanoacrylamide was a Knoevenagel condensation reaction with the aldehyde INT67 catalyzed by trimethylsilyl chloride (TMSCl) to give the final product rilzabrutinib 76 in good yield (70%, Figure 59 b) [ 253 ].

2.5.2. Remibrutinib

Approved on 30 September 2025, Remibrutinib ( 77 , brand name Rhapsido ® , Figure 60 a) is a small molecule for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine therapy, marking it as the first BTK inhibitor approved for this allergic skin condition [ 246 ]. Remibrutinib is an oral, highly selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor developed by Novartis that targets BTK signaling to reduce immune-mediated release of histamine and other pro-inflammatory mediators in conditions driven by mast cells and basophils [ 254 ]. Chemically, it is a small-molecule heterocycle designed for potency, selectivity, and oral bioavailability with a covalent binding mechanism to Cys481 in the BTK active site, giving sustained inhibition with a favorable safety profile compared with less selective agents [ 255 ]. The approval was supported by positive Phase III data demonstrating significant improvements in itch and hive severity and overall disease activity compared with placebo in patients with CSU [ 254 ]. Remibrutinib is also under investigation in other immune-mediated diseases such as chronic inducible urticaria, hidradenitis suppurativa, and food allergy [ 256 ]. It contains an acrylamide moiety. The first synthon is obtained from 1-bromo-5-fluoro-2-methyl-3-nitrobenzene ( INT68 ), which underwent a Suzuki coupling using bis (pinacolato)diboron (B 2 pin 2 ), potassium acetate (KOAc), and PdCl 2 (dppf) in 1,4-dioxane in excellent yield ( INT69 , 92%). The following reduction (catalytic hydrogenation) of the nitro group afforded aniline INT70 (93% yield), which was used to prepare amide INT72 by reacting with methyl ester INT71 using sodium hexamethyldisilazide (NaHMDS) as the base in THF (76%). The second synthon is obtained via reacting pyrimidine INT73 with ammonium hydroxide (NH 4 OH) and BBr 3 to give monochloroaniline INT74 (59%). This was transformed into tertiary amine INT75 via a polymer-bound triphenylphosphine (Smopex 310) in the corresponding Mitsunobu reaction involving tert-butyl (2-hydroxyethyl)(methyl)carbamate INT76 (53%). This reacted with INT72 under Suzuki conditions [(PdCl 2 (PPh 3 ) 2 Na 2 CO 3 in 1,2-Dimethoxyethane/water, DME–H 2 O, 110 °C, 25 min)] to give the precursor INT77 for remibrutinib ( 77 ). The last step involved the deprotection of the BOC group (using TFA) and the formation of acrylamide via propanephosphonic acid anhydride (T 3 P) in a moderate yield (45%, Figure 60 b) [ 253 ].

2.5.3. Aficamten

Approved on 19 December 2025, aficamten ( 78 , brand name Myqorzo ® , Figure 61 a) is a selective small-molecule inhibitor of cardiac myosin developed to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM), a genetic heart condition in which abnormally thickened heart muscle impedes blood flow and causes symptoms like shortness of breath, chest pain, and fatigue [ 244 , 257 ]. It works by binding to cardiac myosin and reducing excessive cross-bridge formation between actin and myosin during the contractile cycle, thereby lowering hypercontractility and improving left ventricular outflow tract obstruction without abolishing normal systolic function [ 258 ]. The synthesis proceeds via the primary amine of the chiral aminoindane intermediate INT78 , which is coupled with 1-methyl-1 H -pyrazole-4-carboxylic acid. The transformation utilizes the carbodiimide coupling agent EDC in combination with 1-Hydroxy-7-azabenzotriazole (HOAt) to drive the condensation efficiently, affording the target drug molecule in an 88% yield while preserving the stereochemical integrity of the chiral center ( Figure 61 b) [ 259 ].

2.5.4. Sevabertinib

Approved on 19 November 2025, sevabertinib ( 79 , brand name Hyrnuo ® , Figure 62 ) is an investigational, orally available small-molecule pan-ERBB tyrosine kinase inhibitor [ 260 ]. It targets members of the ERBB receptor family (including EGFR/HER1, HER2, and HER4) and is being developed primarily for non-small-cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, which are typically resistant to earlier EGFR inhibitors [ 261 , 262 ]. Chemically, sevabertinib is a multi-ring heteroaromatic small molecule, an ATP-mimetic in design, optimized for kinase hinge binding with balanced lipophilicity and oral delivery. Sevabertinib, like most kinase inhibitors, contains multiple aromatic rings with heterocycles and limited polar surface area, giving it moderate to high lipophilicity with some hydrogen-bonding capacity. The piperidin-2-one-containing building block was introduced intact rather than being generated de novo during the synthesis [ 253 ].

2.5.5. Elinzanetant

On 24 October 2025, the FDA approved elinzanetant ( 80 , brand name Lynkuet ® , Figure 63 ) for the treatment of women with moderate-to-severe vasomotor symptoms due to menopause (IPF) [ 263 ]. Elinzanetant was discovered through Bayer’s internal neurokinin receptor antagonist program, originally targeting central nervous system pathways involved in thermoregulation and hormone feedback. Optimization efforts focused on developing a compound that could simultaneously block neurokinin-1 (NK1) and neurokinin-3 (NK3) receptors [ 264 , 265 ]—both implicated in menopausal vasomotor symptoms (VMS) such as hot flashes while maintaining favorable pharmacokinetics and safety [ 266 ]. The compound was selected for development after promising preclinical results showing potent inhibition of substance P [ 267 ] and neurokinin B signaling pathways, with good oral bioavailability and central nervous penetration [ 268 ]. It is a drug-like organic compound with multiple aromatic and heteroaromatic rings, nitrogen-containing functional groups, and amide linkages that enable hydrogen bonding and receptor binding. It has a moderate molecular weight and significant lipophilicity, typical of CNS-active agents, allowing membrane permeability while maintaining receptor selectivity. Elinzanetant contains extensive aromatic and aliphatic regions with limited strongly polar or ionizable functionality, so its overall character is largely lipophilic. The patent EP4431512A1 [ 269 ] mentions “methods of preparing said compounds, intermediate compounds useful for preparing said compounds” but is somewhat general and is directed to a family of compounds (not exclusively elinzanetant). Therefore, the specific step-by-step synthesis for the marketed molecule may be partly confidential.

2.5.6. Brensocatib

Approved by the FDA in August 2025, brensocatib ( 81 , brand name Brinsupri ® , Figure 64 a) is an oral, selective inhibitor of dipeptidyl peptidase 1 (also known as cathepsin C) developed to reduce excessive neutrophil-driven inflammation [ 270 , 271 ]. By blocking activation of neutrophil serine proteases, it aims to limit tissue damage associated with chronic inflammatory lung diseases, particularly non-cystic fibrosis bronchiectasis [ 272 ]. Brensocatib was developed by Insmed Incorporated and demonstrated clinically meaningful reductions in pulmonary exacerbations in Phase 3 trials in patients with bronchiectasis [ 273 ]. Unlike peptide-based protease inhibitors, brensocatib is structurally stable against rapid enzymatic degradation because it lacks a classical peptide backbone, displaying a 1,4-oxazepane-2-carboxamide backbone. The synthesis ( Figure 64 b) involves an amide coupling reaction where EDC activates the carboxylic acid ( INT79 ) to form a reactive intermediate, which is then converted into a more stable active ester by 2-hydroxypyridine- N -oxide (HOPO) to prevent racemization. DIPEA acts as a non-nucleophilic base to free the amine ( INT80 ) and neutralize acidic byproducts, facilitating its attack on the active ester to form INT81 [ 274 ].

2.5.7. Zongertinib

Approved on 8 August 2025, zongertinib ( 82 , brand name Hernexeos ® , Figure 65 a) is an oral, selective HER2 (ERBB2) tyrosine kinase inhibitor developed by Boehringer Ingelheim for the treatment of HER2-mutant non-small-cell lung cancer (NSCLC) [ 275 ]. It works by irreversibly inhibiting HER2 signaling, thereby blocking tumor cell growth driven by activating HER2 mutations [ 276 ]. The acrylamide moiety in zongertinib acts as a covalent warhead that enables irreversible inhibition of the HER2 kinase domain [ 277 ]. In the kinase active site, the electrophilic double bond of the acrylamide reacts with a nucleophilic cysteine residue in HER2 through Michael addition, forming a covalent thioether bond between the inhibitor and the protein [ 277 ]. Its synthesis ( Figure 65 b) proceeds via a primary amine on the piperidine ring of INT82 that acts as the nucleophile, attacking the electrophilic carbonyl carbon of the acryloyl chloride. Elimination of the chloride leaving group forms the amide bond, while DIPEA acts as an acid scavenger to neutralize the hydrochloric acid generated during the process [ 278 ].

2.5.8. Dordaviprone

Approved on 6 August 2025, dordaviprone ( 83 , brand name Modeyso ® , Figure 66 ) is an oral small-molecule imipridone anticancer agent developed by Chimerix that targets mitochondrial protease ClpP and antagonizes the dopamine receptor DRD2, leading to activation of the integrated stress response and induction of tumor cell apoptosis [ 279 ]. It is characterized by a tri-heterocyclic imidazopyridone core structure. Imipridones were originally discovered through screening for compounds that selectively induce tumor cell death without strongly affecting normal cells. Its synthesis is achieved via a copper-catalyzed tandem approach. This strategy selectively activates the specific nucleophilic nitrogen site determined by the geometric constraints of the copper–ligand–substrate complex. This explicitly forces an angular cyclization pathway, delivering the thermodynamically favored angular isomer with absolute regiocontrol [ 280 ].

2.5.9. Delgocitinib

The FDA approved delgocitinib ( 84 , brand name Anzupgo ® , Figure 67 a) on 23 July 2025, for treating adults with moderate-to-severe chronic hand eczema [ 281 ]. This topical pan-Janus kinase inhibitor serves as a non-steroidal alternative for patients who fail to find relief with traditional corticosteroids. It is designed for twice-daily application and works by blocking the signaling pathways responsible for skin inflammation and itching [ 282 ]. The synthesis proceeds via acylation at the azetidine nitrogen ( Figure 67 b). The transformation is a nucleophilic acyl substitution reaction where the secondary amine of the azetidine ring in INT83 attacks the carbonyl carbon of the cyanoacetylating reagent, 1-(2-cyanoacetyl)-3,5-dimethyl-1 H -pyrazole. Non-nucleophilic base DIPEA facilitates the reaction by neutralizing the leaving 3,5-dimethylpyrazole group. This step introduces the specific cyanoacetyl warhead onto the azetidine nitrogen, yielding delgocitinib in 74% yield without perturbing the stereochemistry of the core or the reactive pyrrolopyrimidine scaffold [ 283 ].

2.5.10. Sebetralstat

Approved on 7 July 2025 by the FDA [ 284 ], sebetralstat ( 85 , Ekterly ® , Figure 68 a) is an oral drug developed by KalVista Pharmaceuticals for the on-demand treatment of hereditary angioedema (HAE) attacks [ 284 , 285 ]. Hereditary angioedema (HAE) attacks are characterized by sudden, painful swelling episodes in various parts of the body. These attacks can affect the face, limbs, abdomen, and, most seriously, the airways, potentially leading to life-threatening situations [ 286 ]. Sebetralstat is a selective plasma kallikrein inhibitor designed to prevent the excessive production of bradykinin [ 287 ]—a peptide that increases vascular permeability and causes the painful, potentially life-threatening swelling characteristic of HAE. The most common side effect of sebetralstat is headache [ 288 ]. It features a unique 3-fluoro-4-methoxypyridyl moiety. The transformation is a CDI-mediated amide coupling reaction. The carboxylic acid group on the pyrazole ring of INT84 is first activated in situ by 1,1′-carbonyldiimidazole (CDI) in DMF at 50 °C to form a highly reactive acyl imidazole intermediate. Subsequent nucleophilic attack by the primary amine of (3-fluoro-4-methoxypyridin-2-yl)methanamine onto this activated carbonyl yields the target compound, sebetralstat, with a 78% chemical yield over the course of an overnight reaction ( Figure 68 b) [ 253 ].

2.5.11. Sunvozertinib

Sunvozertinib ( 86 , brand name Zegfrovy ® , Figure 69 a) is an oral, irreversible tyrosine kinase inhibitor (TKI) that minimizes action against wild-type EGFR while specifically targeting EGFR exon 20 insertion mutations and specific HER2 exon 20 insertion mutations. In non-small-cell lung cancer (NSCLC) models, it disrupts angiogenesis and tumor cell proliferation by binding covalently to the kinase [ 289 ].

On 2 July 2025, the FDA granted expedited clearance for adult patients with advanced or metastatic non-small-cell lung cancer (NSCLC) who have EGFR exon 20 insertions following platinum chemotherapy, as identified by an FDA-approved test [ 290 ]. It has one fluorine and one chlorine on the same aromatic ring. The conversion proceeds via a highly regioselective nucleophilic acyl substitution reaction. The primary aniline nitrogen situated on the central benzene ring of INT85 acts as the nucleophile, targeting the electrophilic carbonyl carbon of acryloyl chloride. The reaction runs efficiently at low temperatures between 5 and 10 °C in DMF for 15 min, driven by DIEA, which acts as a base to scavenge the liberated hydrochloric acid. This amidation process specifically installs the crucial acrylamide group onto the scaffold, providing sunvozertinib with a 10% chemical yield ( Figure 69 b) [ 253 ].

2.5.12. Acoltremon

Acoltremon ( 87 , brand name Tryptyr ® , Figure 70 a) was FDA-approved in May 2025 as a first-in-class ophthalmic drug for dry eye disease, acting as a TRPM8 thermoreceptor agonist that stimulates corneal sensory nerves and trigeminal signaling to increase basal tear production with rapid onset, often within one day [ 291 ]. Pharmacologically, it is administered topically as a 0.003% ophthalmic solution (one drop per eye twice daily), producing localized effects with minimal systemic exposure, showing good tolerability with mainly instillation-site pain as the common adverse effect, and demonstrating efficacy in Phase III trials through significant increases in tear production [ 292 ]. Its synthesis starts from chloride ( INT86 ). The transformation is a nucleophilic acyl substitution reaction between a menthol-derived chiral acyl chloride (derived from p-menthane-3-carboxylic acid) and 4-methoxyaniline ( p -anisidine). Mechanistically, the primary amine of the electron-rich aniline acts as the nucleophile, attacking the highly electrophilic carbonyl carbon of the acyl chloride to displace the chloride leaving group. Sodium bicarbonate serves as an inorganic base in this Schotten–Baumann-type coupling to neutralize the hydrochloric acid byproduct, driving the reaction to completion. The reaction selectively forms the amide bond with absolute preservation of the three chiral centers on the cyclohexane ring, yielding acoltremon in an 82% chemical yield [ 293 ].

2.5.13. Defactinib

Avutometinib ( 88 ) and defactinib ( 89 ) were approved together by the FDA as a combination therapy rather than as standalone drugs. On 8 May 2025, the agency granted accelerated approval to the co-packaged regimen marketed as Avmapki Fakzynja Co pack ® , indicated for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have previously received systemic therapy [ 294 ]. Only defactinib contains an amide group ( Figure 71 ). The secondary amide building block was introduced intact rather than being generated de novo during the synthesis [ 253 ].

2.5.14. Atrasentan

Atrasentan ( 90 , Figure 72 ) received its first FDA approval on 2 April 2025, under the brand name Vanrafia ® . The agency granted accelerated approval for its use in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression, specifically to reduce proteinuria, a key surrogate marker of kidney damage [ 295 ]. Pharmacologically, atrasentan is a selective endothelin-A receptor antagonist, designed to block endothelin-mediated vasoconstriction and inflammatory signaling within the glomerulus, thereby reducing protein leakage into urine and potentially slowing structural kidney damage [ 296 ]. The secondary amide building block was introduced intact rather than being generated de novo during the synthesis [ 297 ].

2.5.15. Gepotidacin

Gepotidacin ( 91 , Figure 73 a) was approved by the FDA on 25 March 2025, under the brand name Blujepa ® . The approval covers the oral treatment of uncomplicated urinary tract infections (uUTIs) in female adults and pediatric patients aged 12 years and older who weigh at least 40 kg [ 298 ]. Gepotidacin is notable because it is a first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by targeting both DNA gyrase and topoisomerase IV at a site distinct from fluoroquinolones, helping retain activity against many drug-resistant pathogens [ 299 ]. The process functions as an intramolecular nucleophilic acyl substitution (lactamization). Sodium hydride acts as a strong base to deprotonate the more acidic secondary amine attached to the 1,3-dioxan-5-yl group. This generation of a highly nucleophilic amide anion triggers an intramolecular attack on the neighboring ethyl ester carbonyl carbon, displacing the ethoxide leaving group to close the new six-membered ring. Ammonium chloride is subsequently added as a mild acid quench to work up the reaction, successfully assembling the fused heterocyclic scaffold while leaving the acid-sensitive acetonide protective group intact [ 300 ].

2.5.16. Vimseltinib

Vimseltinib ( 92 , Figure 74 ) received FDA approval on 14 February 2025, under the brand name Romvimza ® , for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) in cases where surgical resection would likely cause severe morbidity or worsening functional limitation [ 301 ]. Vimseltinib is an oral colony-stimulating factor-1 receptor (CSF1R) switch-control kinase inhibitor that targets the signaling pathway responsible for recruiting inflammatory cells that drive TGCT growth, providing a targeted systemic therapy option for patients whose disease is not amenable to surgery [ 302 ].

2.5.17. Suzetrigine

On 30 January 2025, the FDA approved suzetrigine ( 93 , brand name Journavx ® , Figure 75 ) as the first non-opioid, selective NaV1.8 sodium channel inhibitor for treating moderate-to-severe acute pain in adults [ 303 ]. This oral medication targets peripheral pain signals without impacting central nervous system receptors, providing an alternative to traditional pain management. Suzetrigine’s approval emphasizes that Nav1.8 targeting may be a crucial tactic for managing moderate to severe acute pain [ 304 ]. At the moment, the number of Nav1.8 inhibitors in clinical trials is still low. With an IC 50 of 0.7 nM and more than 31,000-fold selectivity against other NaV isoforms, VX-548 is a superbly selective inhibitor of NaV1.8. Important off-target effects on NaV1.4 (muscle contraction) and NaV1.5 (cardiac rhythm) are prevented by this selectivity [ 305 ]. Its structure and synthesis can be noted in [ 306 , 307 ].

2.5.18. Elamipretide

Approved on 19 September 2025, elamipretide ( 94 , brand name Forzinity ® , Figure 76 ) is a first-in-class, mitochondria-targeting tetrapeptide developed for treating diseases characterized by mitochondrial dysfunction [ 308 ]. In particular, it is the first approved treatment for Barth syndrome, a rare mitochondrial disease affecting primarily males [ 309 ]. Elamipretide has two positively charged amino acids (D-Arg and Lys), which allow it to preferentially target the inner mitochondrial membrane, which has a high negatively charged cardiolipin content [ 309 ].

3. Discussion

The data shown in Figure 77 confirm that the amide bond remains a cornerstone of medicinal chemistry. In four out of the five years analyzed, nearly half (or more) of all New Chemical Entities (NCEs) contained at least one amide group. Only 2022 saw a significant drop in both total NCEs (22) and amide-containing entities (7). This general trend (for years 2021, 2023, 2024, and 2025) is likely due to the amide’s unique ability to provide structural rigidity and act as both a hydrogen bond donor and acceptor, which is critical for high-affinity binding to protein targets.

In the evolving landscape of medicinal chemistry, the shift toward structural rigidity has become a hallmark of successful drug design. A longitudinal analysis of FDA approvals from 2021 to 2025 reveals that cyclic amides (lactams) consistently represent a significant portion of amide-containing therapeutics, ranging from 25% to 37% of annual approvals ( Figure 78 ). This trend underscores a deliberate move away from flexible acyclic chains in favor of the enhanced metabolic stability and superior binding affinity offered by cyclic architectures. Seven out of a total (amide-containing) nineteen drugs in 2021 (approved by the FDA) contain at least one cyclic amide group. In 2022, two out of seven drugs contain at least one cyclic amide group. In 2023, 4 out of 16 drugs contain at least one cyclic amide group. In 2024, 5 out of 16 drugs contain at least one cyclic amide group. In 2025, 5 out of 18 drugs contain at least one cyclic amide group. The data show that cyclic amides (lactams) consistently represent a significant portion (roughly 25–30%) of amide-containing drugs approved by the FDA between 2021 and 2025. This trend can be rationalized through several key medicinal chemistry advantages that cyclic amides offer over their acyclic counterparts. The enhanced reactivity of β-lactams arises from the combined effects of significant ring strain and reduced amide resonance stabilization, as demonstrated in computational and spectroscopic studies [ 310 ]. Cyclic amide (pyridone/lactam) motifs represent privileged scaffolds in kinase inhibitor design, as their conformational rigidity and pre-organized hydrogen-bond donor–acceptor geometry enable consistent adenine-mimicking interactions with the hinge region—an effect exemplified by inhibitors such as Staurosporine, pyridone 6, and hydroxyfasudil, which all exploit cyclic amide groups to achieve high-affinity binding within the ATP pocket [ 311 ]. Conformational effects, such as distortion caused by ring strain or steric interactions, bridged amides, and specially designed cyclic systems that physically lock the amide into a non-planar geometry, are strategies used in organic chemistry to study and control amide reactivity by disrupting resonance [ 312 ].

The continued presence of cyclic amides is also driven by their dominance in specific therapeutic areas: Antibiotics; the lactam ring (a 4-membered cyclic amide) remains the most common structural motif in antibiotics like penicillins and cephalosporins [ 313 ]. In anticancer and rare diseases, there has been a growing trend in the approval of cyclic peptides and macrocycles (large rings containing multiple amides), which are used to target complex protein–protein interactions that smaller, linear molecules cannot [ 314 ]. The data shown in Figure 79 highlights that the number of amide-containing drugs remained relatively stable over the five-year period, fluctuating between 16 and 19 compounds per year (except for the year 2022). This suggests that amide functional groups continue to be consistently represented in approved or analyzed drug molecules. When distinguishing between amide subtypes, secondary acyclic amides were more prevalent than primary acyclic amides in every year examined. Secondary amides ranged from 4 to 13 occurrences, whereas primary acyclic amides appeared only 1–2 times per year, indicating that primary amides are comparatively rare in drug structures. It is important to note that each compound was counted once if it contained at least one instance of the functional group (e.g., at least one amide or at least one primary acyclic amide), rather than counting the total number of functional groups per molecule. Therefore, the values reflect compound prevalence, not functional group frequency. Primary acyclic amides were markedly underrepresented compared to secondary acyclic amides in all years analyzed. This trend is consistent with established medicinal chemistry principles: primary amides are more polar and often more susceptible to hydrolysis and enzymatic degradation. In contrast, secondary amides typically provide greater conformational rigidity, improved membrane permeability, and enhanced metabolic stability, which makes them more favorable in the design of orally bioavailable small-molecule drugs.

As can be seen from Table 1 , the most represented therapeutic area is oncology, accounting for approximately 35–40% of all drugs, including subcategories such as targeted therapy, hematologic malignancies, CNS tumors, and diagnostics/radiopharmaceuticals. Other prominent areas include immunology/autoimmune (≈15%), infectious diseases (≈10%), and neurology/rare diseases (≈10%). Each year has a strong oncology presence, reflecting ongoing investment in cancer-targeted therapies and imaging agents. Subcategories like hematologic malignancies and solid tumor-targeted therapies are increasingly frequent from 2023 to 2025. There has been a rise in rare disease therapies: drugs for rare metabolic, mitochondrial, and neurodevelopmental disorders (e.g., omaveloxolone, trofinetide, elamipretide) appear predominantly in 2023–2025, highlighting a trend toward niche indications. Immunology has seen an expansion: autoimmune and allergy-targeted agents like rilzabrutinib, remibrutinib, and ritlecitinib show sustained growth, suggesting continued focus on immune-modulating therapies. Although fewer in number, key antiviral and antibacterial therapies (e.g., nirmatrelvir + ritonavir, rezafungin, and gepotidacin) highlight responsiveness to emerging infectious threats. Regarding diversification in therapeutic areas, other categories such as cardiology, women’s health/endocrine, ophthalmology, and diagnostic imaging reflect a growing diversity in the applications of amide-containing molecules beyond oncology and immunology.

The ubiquity of the amide linkage in bioactive small molecules (seen in this article) has driven the optimization of diverse synthetic methodologies ( Figure 80 ) within both discovery and process development phases. Classical approaches rely on the generation of highly electrophilic acyl halides via reagents such as thionyl chloride or oxalyl chloride. While highly efficient for sterically hindered systems, these conditions are frequently bypassed for complex scaffolds due to potential epimerization and functional group incompatibility. Conversely, the frequent deployment of acryloyl chloride highlights its indispensable specialized utility in appending acrylamide motifs acting as covalent warheads in targeted covalent inhibitors. To mitigate epimerization and establish milder reaction regimes, peptide coupling reagents are widely utilized. Carbodiimide architectures, notably EDC or DCC paired with suppressive nucleophilic additives like HOBt or HOAt, remain standard workhorses due to controllable kinetics and predictable profiles. For highly demanding or sterically constrained couplings, aminium/uronium and phosphonium systems such as HATU, HBTU, TPTU, and PyBOP are preferred. Specifically, HATU leverages a neighboring-group autocatalytic effect to deliver superior conversion rates in discovery chemistry. For scalable green chemistry applications and process development, alternatives like propylphosphonic anhydride (T3P) and triazine-based activators like 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) are increasingly favored, owing to their low epimerization risks, mild ambient conditions, and water-soluble byproducts that simplify downstream isolation. Furthermore, atom-economical reagents like carbonyldiimidazole (CDI) and N , N ’-disuccinimidyl carbonate (DSC) provide clean pathways through transient imidazolide or active carbonate chemistry without requiring exogenous organic bases.

4. FDA-Approved Drugs Containing Amide in 2026

The continuous wave of 2026 FDA approvals for small-molecule therapeutics ( Figure 81 ) like relacorilant, a sulfonamide, and orforglipron (a tertiary amide) underscores the irreplaceable impact of the amide functional group in modern drug design, where its exceptional metabolic stability and precise geometric constraint act as the structural backbone needed to optimize binding affinity, enhance oral bioavailability, and successfully target complex disease pathways.

5. Concluding Remarks

Over the last five years (2021–2025), FDA-approved drugs containing amide functionalities have demonstrated a remarkable breadth of therapeutic applications, spanning oncology, immunology, neurology, infectious diseases, and rare metabolic disorders. Our analysis of 76 compounds highlights oncology as the dominant therapeutic area, reflecting sustained efforts in targeted cancer therapies, radiopharmaceutical diagnostics, and hematologic malignancy management. Concurrently, there is a notable increase in drugs addressing rare diseases and autoimmune conditions, signaling a strategic shift toward niche indications where unmet medical needs remain high. The emergence of antiviral and antibacterial amide-containing agents underscores the continued importance of amides in rapid response to infectious threats, exemplified by COVID-19 therapeutics and novel antibacterial compounds. The data also suggest an evolving landscape in pharmaceutical design, with amide moieties contributing to both bioavailability and solubility optimization, enabling effective drug delivery across diverse molecular classes. The consistent approval of amide-containing molecules across multiple therapeutic areas underscores their versatility and continued relevance in medicinal chemistry. Overall, these trends highlight the dual role of amide functionality in both pharmacological efficacy and favorable physicochemical properties, reinforcing its status as a core structural element in modern drug discovery. Ultimately, the evolution of amide bond synthesis, transitioning from classical, aggressive acyl halide reagents to highly refined, green, and atom-economical coupling frameworks, underscores the crucial bridge between innovative synthetic methodology and the efficient, sustainable delivery of modern therapeutic agents. Future research and development are likely to continue leveraging amide chemistry to address both common and rare diseases, while also optimizing solubility and pharmacokinetic profiles for enhanced clinical performance.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The author declares no conflict of interest.

References

1. Li G. Ma S. Szostak M. Amide Bond Activation: The Power of Resonance Trends Chem. 2020 2 914 928 10.1016/j.trechm.2020.08.001

2. Schnabel A. Athmer B. Manke K. Schumacher F. Cotinguiba F. Vogt T. Identification and Characterization of Piperine Synthase from Black Pepper, Piper nigrum L. Commun. Biol. 2021 4 445 10.1038/s42003-021-01967-9 33833371 PMC8032705

3. Tiwari A. Mahadik K.R. Gabhe S.Y. Piperine: A Comprehensive Review of Methods of Isolation, Purification, and Biological Properties Med. Drug Discov. 2020 7 100027 10.1016/j.medidd.2020.100027

4. Wang N. Zhou X. Zhang T. Jian W. Sun Z. Qi P. Feng Y. Liu H. Liu L. Yang S. Capsaicin from Chili Peppers and Its Analogues and Their Valued Applications: An Updated Literature Review Food Res. Int. 2025 208 116034 10.1016/j.foodres.2025.116034 40263816

5. Jayan L.S. Rajan S.S. Mujahid S.M. Sharma S. Wani K.M. Capsaicin: An in-Depth Review of Its Chemical Properties, Health Benefits, and Challenges in Food Applications Food Prod. Process. Nutr. 2025 7 47 10.1186/s43014-025-00321-4

6. Maiese K. Chong Z.Z. Hou J. Shang Y.C. The Vitamin Nicotinamide: Translating Nutrition into Clinical Care Molecules 2009 14 3446 3485 10.3390/molecules14093446 19783937 PMC2756609

7. Camillo L. Zavattaro E. Savoia P. Nicotinamide: A Multifaceted Molecule in Skin Health and Beyond Medicina 2025 61 254 10.3390/medicina61020254 40005371 PMC11857428

8. Valeur E. Bradley M. Amide Bond Formation: Beyond the Myth of Coupling Reagents Chem. Soc. Rev. 2009 38 606 631 10.1039/B701677H 19169468

9. Vassilev N.G. Ivanov I.C. A Small Change in Structure, a Big Change in Flexibility Molecules 2023 28 8004 10.3390/molecules28248004 38138494 PMC10745939

10. Mahesh S. Tang K.-C. Raj M. Amide Bond Activation of Biological Molecules Molecules 2018 23 2615 10.3390/molecules23102615 30322008 PMC6222841

11. Kearly A. Peptides: Powerful, Pervasive, and Full of Potential J. Exp. Bot. 2025 76 5629 5633 10.1093/jxb/eraf379 41219158 PMC12605741

12. Reghupaty S.C. Dall N.R. Svensson K.J. Hallmarks of the Metabolic Secretome Trends Endocrinol. Metab. 2024 35 49 61 10.1016/j.tem.2023.09.006 37845120 PMC10841501

13. Orchard I. Belanger J.H. Lange A.B. Proctolin: A Review with Emphasis on Insects J. Neurobiol. 1989 20 470 496 10.1002/neu.480200515 2568390

14. Fridkin M. Najjar V.A. Tuftsin: Its Chemistry, Biology, and Clinical Potentia Crit. Rev. Biochem. Mol. Biol. 1989 24 1 40 10.3109/10409238909082550 2667894

15. Uvnäs-Moberg K. The Physiology and Pharmacology of Oxytocin in Labor and in the Peripartum Period Am. J. Obstet. Gynecol. 2024 230 S740 S758 10.1016/j.ajog.2023.04.011 38462255

16. Freo U. Ruocco C. Valerio A. Scagnol I. Nisoli E. Paracetamol: A Review of Guideline Recommendations J. Clin. Med. 2021 10 3420 10.3390/jcm10153420 34362203 PMC8347233

17. Mallet C. Desmeules J. Pegahi R. Eschalier A. An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact J. Pain Res. 2023 16 1081 1094 10.2147/JPR.S393809 37016715 PMC10066900

18. Gudin J. Nalamachu S. Utility of Lidocaine as a Topical Analgesic and Improvements in Patch Delivery Systems Postgrad. Med. 2020 132 28 36 10.1080/00325481.2019.1702296 31900074

19. Karunarathna I. Hapuarachchi T. Gunasena P. Ekanayake U. Rajapaksha S. Gunawardana K. Aluthge P. Bandara S. Jayawardana A. De Alvis K. Amoxicillin in the Management of Common Bacterial Infections: A Clinical Overview 2024 Available online: https://www.researchgate.net/publication/383230032_Amoxicillin_in_the_Management_of_Common_Bacterial_Infections_A_Clinical_Overview?channel=doi&linkId=66c37a735f116e7c5306c5b6&showFulltext=true (accessed on 2 May 2026)

20. Dodd-Butera T. Broderick M. Diazepam Encyclopedia of Toxicology Elsevier Amsterdam, The Netherlands 2005 783 785

21. Heel R.C. Brogden R.N. Speight T.M. Avery G.S. Captopril: A Preliminary Review of Its Pharmacological Properties and Therapeutic Efficacy Drugs 1980 20 409 452 10.2165/00003495-198020060-00001 7009133

22. Pubmed Search Available online: https://pubmed.ncbi.nlm.nih.gov/?term=amide+bond&filter=years.2000-2026 (accessed on 2 May 2026)

23. Lubberink M. Finnigan W. Flitsch S.L. Biocatalytic Amide Bond Formation Green Chem. 2023 25 2958 2970 10.1039/D3GC00456B

24. Alfano A.I. Lange H. Brindisi M. Amide Bonds Meet Flow Chemistry: A Journey into Methodologies and Sustainable Evolution ChemSusChem 2022 15 e202102708 10.1002/cssc.202102708 35244343

25. Dorr B.M. Fuerst D.E. Enzymatic Amidation for Industrial Applications Curr. Opin. Chem. Biol. 2018 43 127 133 10.1016/j.cbpa.2018.01.008 29414531

26. Drug Containing Amide Available online: https://pubmed.ncbi.nlm.nih.gov/?term=drug+containing+amide&filter=years.2000-2026 (accessed on 2 May 2026)

27. A Perspective of the Amide Group Containing FDA Approved Anticancer Drugs from 2021–2022 (A Review)|Russian Journal of Bioorganic Chemistry|Springer Nature Link Available online: https://link.springer.com/article/10.1134/S1068162023060018 (accessed on 25 January 2026)

28. De La Torre B.G. Albericio F. The Pharmaceutical Industry in 2024: An Analysis of the FDA Drug Approvals from the Perspective of Molecules Molecules 2025 30 482 10.3390/molecules30030482 39942587 PMC11820978

29. Gul Z. Henary M. Pafolacianine, the Magic Wand of Intraoperative Imaging of Folate-Receptor Positive Ovarian Cancer Ann. Transl. Med. 2023 11 394 10.21037/atm-23-467 37970599 PMC10632580

30. Dindere M.E. Tanca A. Rusu M. Liehn E.A. Bucur O. Intraoperative Tumor Detection Using Pafolacianine Int. J. Mol. Sci. 2022 23 12842 10.3390/ijms232112842 36361630 PMC9658182

31. Sarkaria I.S. Martin L.W. Rice D.C. Blackmon S.H. Slade H.B. Singhal S. Ebright M.I. Gangadharan S.P. Louie B.E. Murthy S.C. Pafolacianine for Intraoperative Molecular Imaging of Cancer in the Lung: The ELUCIDATE Trial J. Thorac. Cardiovasc. Surg. 2023 166 e468 e478 10.1016/j.jtcvs.2023.02.025 37019717 PMC12507096

32. Wang Q. Han J. Sorochinsky A. Landa A. Butler G. Soloshonok V.A. The Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorine Pharmaceuticals 2022 15 999 10.3390/ph15080999 36015147 PMC9416721

33. Pamuk G.E. Chow E.C.Y. Ionan A.C. Chen H. Lee S.-L. Hsu V. Grimstein M. Zheng N. Sun J. Charlab R. FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation Clin. Cancer Res. 2024 30 4266 4271 10.1158/1078-0432.CCR-24-1086 39088257 PMC11444873

34. Deeks E.D. Asciminib: First Approval Drugs 2022 82 219 226 10.1007/s40265-021-01662-3 35041175

35. Hoch M. Huth F. Manley P.W. Loisios-Konstantinidis I. Combes F.P. Li Y.F. Fu Y. Sy S.K.B. Obourn V. Chakraborty A. Clinical Pharmacology of Asciminib: A Review Clin. Pharmacokinet. 2024 63 1513 1528 10.1007/s40262-024-01428-6 39467980 PMC11573869

36. Ghasoub R. Hamad A. El Akiki S. Fareed S. Ellahie A. Ismael O. Yassin M.A. Therapeutic Positioning of Asciminib in Chronic Myeloid Leukemia Patients Previously Treated with Multiple Tyrosine Kinase Inhibitors in Qatar Discov. Oncol. 2025 16 1959 10.1007/s12672-025-03759-7 41129058 PMC12550086

37. Tuzikiewicz A. Wawrzyniak W. Kutner A. Żołek T. Advances in Targeting BCR-ABLT315I Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules Molecules 2026 31 341 10.3390/molecules31020341 41599389 PMC12843680

38. Schoepfer J. Jahnke W. Berellini G. Buonamici S. Cotesta S. Cowan-Jacob S.W. Dodd S. Drueckes P. Fabbro D. Gabriel T. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 J. Med. Chem. 2018 61 8120 8135 10.1021/acs.jmedchem.8b01040 30137981

39. Maruyama Y. Yoshida T. Maruyama I. Pharmacological and Clinical Profiles of Avacopan (TAVNEOS ® Capsule), a Selective C5a Receptor Antagonist Folia Pharmacol. Jpn. 2023 158 399 407 10.1254/fpj.22161 37460300

40. Lee A. Avacopan: First Approval Drugs 2022 82 79 85 10.1007/s40265-021-01643-6 34826105

41. Boinpally R. Shebley M. Trugman J.M. Atogepant: Mechanism of Action, Clinical and Translational Science Clin. Transl. Sci. 2024 17 e13707 10.1111/cts.13707 38266063 PMC10777605

42. Martelletti P. Cipolla F. Capi M. Curto M. Lionetto L. Atogepant. Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist, Preventive Treatment of Migraine Drugs Future 2020 45 285 10.1358/dof.2020.45.5.3123467

43. Cohen F. Yuan H. Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations Ther. Clin. Risk Manag. 2022 18 447 456 10.2147/TCRM.S348724 35493707 PMC9043257

44. Ailani J. Lipton R.B. Goadsby P.J. Guo H. Miceli R. Severt L. Finnegan M. Trugman J.M. Atogepant for the Preventive Treatment of Migraine N. Engl. J. Med. 2021 385 695 706 10.1056/NEJMoa2035908 34407343

45. Wang J. Lam D. Yang J. Hu L. Discovery of Mobocertinib, a New Irreversible Tyrosine Kinase Inhibitor Indicated for the Treatment of Non-Small-Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Med. Chem. Res. 2022 31 1647 1662 10.1007/s00044-022-02952-5 36065226 PMC9433531

46. Duke E.S. Stapleford L. Drezner N. Amatya A.K. Mishra-Kalyani P.S. Shen Y.-L. Maxfield K. Zirkelbach J.F. Bi Y. Liu J. FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Clin. Cancer Res. 2023 29 508 512 10.1158/1078-0432.CCR-22-2072 36112541 PMC9898076

47. Riely G.J. Neal J.W. Camidge D.R. Spira A.I. Piotrowska Z. Costa D.B. Tsao A.S. Patel J.D. Gadgeel S.M. Bazhenova L. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial Cancer Discov. 2021 11 1688 1699 10.1158/2159-8290.CD-20-1598 33632775 PMC8295177

48. De la Fuente E.C. García M.E.O. Martín I.O. Berlinches A.B. Rueda A.G. Alfranca Y.L. Garrido P. Response to Mobocertinib in a Patient with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion after Several Therapies Including Amivantamab Curr. Probl. Cancer Case Rep. 2022 5 100145 10.1016/j.cpccr.2022.100145

49. Yi S. Kim I. Hager R. Strazzeri M.M. Garrard L. Matsubayashi T. Mehta R. Food and Drug Administration Approval Summary: Odevixibat (Bylvay) for the Treatment of Pruritus with Progressive Familial Intrahepatic Cholestasis Gastro Hep Adv. 2025 4 100596 10.1016/j.gastha.2024.100596 40454003 PMC12126724

50. Marx M. Hartleif S. Hilberath J. Berg C.P. Tsiflikas I. Singer S. Sturm E. Practical Considerations for Odevixibat Treatment in Patients with Progressive Familial Intrahepatic Cholestasis: A Single-Center Case Series J. Clin. Med. 2024 13 7508 10.3390/jcm13247508 39768432 PMC11676709

51. Thompson R.J. Arnell H. Artan R. Baumann U. Calvo P.L. Czubkowski P. Dalgic B. D’Antiga L. Durmaz Ö. Fischler B. Odevixibat Treatment in Progressive Familial Intrahepatic Cholestasis: A Randomised, Placebo-Controlled, Phase 3 Trial Lancet Gastroenterol. Hepatol. 2022 7 830 842 10.1016/S2468-1253(22)00093-0 35780807

52. Przepiorka D. Le R.Q. Ionan A. Li R.-J. Wang Y.-H. Gudi R. Mitra S. Vallejo J. Okusanya O.O. Ma L. FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy Clin. Cancer Res. 2022 28 2488 2492 10.1158/1078-0432.CCR-21-4176 35135839 PMC9197942

53. Ali F. Ilyas A. Belumosudil with ROCK-2 Inhibition: Chemical and Therapeutic Development to FDA Approval for the Treatment of Chronic Graft-versus-Host Disease Curr. Res. Transl. Med. 2022 70 103343 10.1016/j.retram.2022.103343 35339032

54. Wang X. Liu Y. Chen T. Yao H. Song Q. Zhang X. ROCK 2 Inhibition with Belumosudil for the Treatment of Chronic Graft-versus-Host Disease: A Narrative Review Ther. Adv. Hematol. 2025 16 20406207251367462 10.1177/20406207251367462 40951719 PMC12423532

55. Heidenreich S. Egger-Heidrich K. Halter J.P. Jost L. Stölzel F. Perl M. Denk A. Edinger M. Herr W. Kröger N. Safety and Efficacy of the ROCK-2-Inhibitor Belumosudil in cGvHD Treatment—A Retrospective, German-Swiss Multicenter Real-World Data Analysis Bone Marrow Transplant. 2025 60 439 446 10.1038/s41409-024-02507-9 39809902 PMC11971036

56. Rathje K. Gagelmann N. Heidenreich S. Richter J. Marquard F.E. Massoud R. Klyuchnikov E. Lueck C. Rudolph I. Ayuk F. Belumosudil for Chronic Graft-Versus-Host Disease: A Systematic Review and Meta-Analysis Transplant. Cell. Ther. 2025 32 450.e1–450.e13 10.1016/j.jtct.2025.11.019 41241260

57. Belumosudil LiverTox: Clinical and Research Information on Drug-Induced Liver Injury National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD, USA 2012 31643176

58. Kim E. Cole B. Sweetnam P. Wong E. Metabolic Inhibitors WO2012040499 29 March 2012

59. Bakris G.L. Agarwal R. Anker S.D. Pitt B. Ruilope L.M. Rossing P. Kolkhof P. Nowack C. Schloemer P. Joseph A. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes N. Engl. J. Med. 2020 383 2219 2229 10.1056/NEJMoa2025845 33264825

60. Haq N. Uppal P. Abedin T. Lala A. Finerenone: Potential Clinical Application Across the Spectrum of Cardiovascular Disease and Chronic Kidney Disease J. Clin. Med. 2025 14 3213 10.3390/jcm14093213 40364247 PMC12539649

61. Ruan S. Zhang W. Yan G. Zhang X. Synthesis Method for Finerenone and Intermediate Thereof WO2023109968 22 June 2023

62. Rehan S.T. Siddiqui A.H. Khan Z. Imran L. Syed A.A. Tahir M.J. Jassani Z. Singh M. Asghar M.S. Ahmed A. Samidorphan/Olanzapine Combination Therapy for Schizophrenia: Efficacy, Tolerance and Adverse Outcomes of Regimen, Evidence-Based Review of Clinical Trials Ann. Med. Surg. 2022 79 104115 10.1016/j.amsu.2022.104115 35860157 PMC9289510

63. Monahan C. McCoy L. Powell J. Gums J.G. Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia Ann. Pharmacother. 2022 56 1049 1057 10.1177/10600280211070330 35040357

64. ChemicalBook Samidorphan: Synthesis and Introduction ChemicalBook Inc. Albany, NY, USA 2024 Available online: https://www.chemicalbook.com/article/samidorphan-synthesis-and-introduction.htm (accessed on 2 May 2026)

65. Blair H.A. Sotorasib: First Approval Drugs 2021 81 1573 1579 10.1007/s40265-021-01574-2 34357500 PMC8531079

66. Higgins J.P. Carlisle J.W. Moniri N.H. Gupta S. Oduah E.I. Leal T. Sotorasib for the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer Future Oncol. 2025 21 63 71 10.1080/14796694.2024.2430172 39601038 PMC11789721

67. Retmana I.A. Loos N.H.C. Schinkel A.H. Beijnen J.H. Sparidans R.W. Quantification of KRAS Inhibitor Sotorasib in Mouse Plasma and Tissue Homogenates Using Liquid Chromatography-Tandem Mass Spectrometry J. Chromatogr. B 2021 1174 122718 10.1016/j.jchromb.2021.122718 33957355

68. Kocienski P. Synthesis of Sotorasib Synfacts 2021 17 1071 10.1055/s-0040-1720181

69. Keam S.J. Piflufolastat F 18: Diagnostic First Approval Mol. Diagn. Ther. 2021 25 647 656 10.1007/s40291-021-00548-0 34292532

70. Voter A.F. Werner R.A. Pienta K.J. Gorin M.A. Pomper M.G. Solnes L.B. Rowe S.P. Piflufolastat F-18 ( 18 F-DCFPyL) for PSMA PET Imaging in Prostate Cancer Expert Rev. Anticancer. Ther. 2022 22 681 694 10.1080/14737140.2022.2081155 35603510

71. Basuli F. Phelps T.E. Zhang X. Woodroofe C.C. Roy J. Choyke P.L. Swenson R.E. Jagoda E.M. Fluorine-18 Labeled Urea-Based Ligands Targeting Prostate-Specific Membrane Antigen (PSMA) with Increased Tumor and Decreased Renal Uptake Pharmaceuticals 2022 15 597 10.3390/ph15050597 35631423 PMC9144807

72. Benedetto Tiz D. Bagnoli L. Rosati O. Marini F. Sancineto L. Santi C. New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use Molecules 2022 27 1643 10.3390/molecules27051643 35268744 PMC8912053

73. Kollins S.H. Braeckman R. Guenther S. Barrett A.C. Mickle T.C. Oh C. Marraffino A. Cutler A.J. Brams M.N. A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder J. Child. Adolesc. Psychopharmacol. 2021 31 597 609 10.1089/cap.2021.0077 34714120

74. D’Arrigo T. Med Check: Qelbree and ADHD; Lacmital and Heart Disease; FDA and Atogepant; Azstarys and ADHD; FDA and CBD; Daridorexant and Insonnia Psychiatr. News 2021 56 appi.pn.2021.5.7 10.1176/appi.pn.2021.5.7

75. Braeckman R. Guenther S. Mickle T.C. Barrett A.C. Smith A. Oh C. Dose Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity Disorder J. Child Adolesc. Psychopharmacol. 2022 32 288 295 10.1089/cap.2022.0015 35666231 PMC9245728

76. Oya M. Matsuoka K. Kubota M. Kitamura S. Kataoka Y. Kokubo N. Takahata K. Seki C. Endo H. Tagai K. Effects of Extended-Release Methylphenidate on Dopamine and Norepinephrine Transporters in Adults with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Dual-Tracer PET Study Psychiatry Clin. Neurosci. 2026 80 48 54 10.1111/pcn.13911 41128391 PMC12757760

77. Dhillon S. Melphalan Flufenamide (Melflufen): First Approval Drugs 2021 81 963 969 10.1007/s40265-021-01522-0 33961277

78. Richardson P.G. Oriol A. Larocca A. Bladé J. Cavo M. Rodriguez-Otero P. Leleu X. Nadeem O. Hiemenz J.W. Hassoun H. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma J. Clin. Oncol. 2021 39 757 767 10.1200/JCO.20.02259 33296242 PMC8078327

79. Olivier T. Prasad V. The Approval and Withdrawal of Melphalan Flufenamide (Melflufen): Implications for the State of the FDA Transl. Oncol. 2022 18 101374 10.1016/j.tranon.2022.101374 35196605 PMC8866737

80. Yuan S. Wang D.-S. Liu H. Zhang S.-N. Yang W.-G. Lv M. Zhou Y.-X. Zhang S.-Y. Song J. Liu H.-M. New Drug Approvals for 2021: Synthesis and Clinical Applications Eur. J. Med. Chem. 2023 245 114898 10.1016/j.ejmech.2022.114898 36370552

81. Benedetto Tiz D. Rosati O. Sancineto L. Sulfur- and Phosphorus-Containing FDA Approved Drugs in the Last Five Years (2020–2024): A Journey among Small Molecules Phosphorus Sulfur. Silicon Relat. Elem. 2025 1 39 10.1080/10426507.2025.2496521

82. Dhillon S. Trilaciclib: First Approval Drugs 2021 81 867 874 10.1007/s40265-021-01508-y 33861388

83. FDA New Oncology Drugs/Indications Approved by the FDA: Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression J. Hematol. Oncol. Pharm. 2021 11 105 109

84. Patel T.I. Joshi J.N. Valvezan A.J. Moschitto M.J. A Review of Trilaciclib, a First-in-Class Cyclin-Dependent Kinase 4/6 Inhibitor, for the Management of Metastatic Small-Cell Lung Cancer Med. Chem. Res. 2024 33 1757 1768 10.1007/s00044-024-03288-y

85. Błaszkowska M. Specht-Szwoch Z. Dziadziuszko R. Tepotinib for Advanced Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations ESMO Open 2022 7 100449 10.1016/j.esmoop.2022.100449 35334419 PMC8956790

86. Paik P.K. Felip E. Veillon R. Sakai H. Cortot A.B. Garassino M.C. Mazieres J. Viteri S. Senellart H. Van Meerbeeck J. Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations N. Engl. J. Med. 2020 383 931 943 10.1056/NEJMoa2004407 32469185 PMC8422679

87. Albers J. Friese-Hamim M. Clark A. Schadt O. Walter-Bausch G. Stroh C. Johne A. Karachaliou N. Blaukat A. The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations Mol. Cancer Ther. 2023 22 833 843 10.1158/1535-7163.MCT-22-0537 36999986 PMC10320478

88. Ji M. Ganesan S. Xia B. Huo Y. Targeting C-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications Cancers 2025 17 1493 10.3390/cancers17091493 40361420 PMC12070916

89. Heo Y.-A. Voclosporin: First Approval Drugs 2021 81 605 610 10.1007/s40265-021-01488-z 33788181 PMC8010786

90. Ashinze P. Mafua N. Banerjee S. Obafemi E. Eniola A. Emmanuel E. Edache A.O. Ozioma C.B. Wireko A.A. Abdul-Rahman T. Voclosporin: A Comprehensive Review of Its Role as a Novel Calcineurin Inhibitor in the Management of Systemic Lupus Erythematosus Medicine 2025 104 e42858 10.1097/MD.0000000000042858 40550096 PMC12187296

91. Kale A. Shelke V. Lei Y. Gaikwad A.B. Anders H.-J. Voclosporin: Unique Chemistry, Pharmacology and Toxicity Profile, and Possible Options for Implementation into the Management of Lupus Nephritis Cells 2023 12 2440 10.3390/cells12202440 37887284 PMC10605893

92. Rovin B.H. Teng Y.K.O. Ginzler E.M. Arriens C. Caster D.J. Romero-Diaz J. Gibson K. Kaplan J. Lisk L. Navarra S. Efficacy and Safety of Voclosporin versus Placebo for Lupus Nephritis (AURORA 1): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial Lancet 2021 397 2070 2080 10.1016/S0140-6736(21)00578-X 33971155

93. Mok C.C. Calcineurin Inhibitors in Systemic Lupus Erythematosus Best Pract. Res. Clin. Rheumatol. 2017 31 429 438 10.1016/j.berh.2017.09.010 29224682

94. Taki E. Soleimani F. Asadi A. Ghahramanpour H. Namvar A. Heidary M. Cabotegravir/Rilpivirine: The Last FDA-Approved Drug to Treat HIV Expert Rev. Anti Infect. Ther. 2022 20 1135 1147 10.1080/14787210.2022.2081153 35596583

95. McGowan J.P. Vail R.M. Shah S.S. Fine S.M. Merrick S.T. Radix A.E. Rodrigues J. Hoffmann C.J. Norton B.L. Gonzalez C.J. Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults New York State Department of Health AIDS Institute Clinical Guidelines Johns Hopkins University Baltimore, MD, USA 2025 34379373

96. Jóźwik I.K. Passos D. Lyumkis D. Structural Biology of HIV Integrase Strand Transfer Inhibitors Trends Pharmacol. Sci. 2020 41 611 626 10.1016/j.tips.2020.06.003 32624197 PMC7429322

97. Ziegler R.E. Desai B.K. Jee J. Gupton B.F. Roper T.D. Jamison T.F. 7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir Angew. Chem. Int. Ed. 2018 57 7181 7185 10.1002/anie.201802256 29756689 PMC6033037

98. Difelikefalin LiverTox: Clinical and Research Information on Drug-Induced Liver Injury National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD, USA 2012 31643176

99. Beck T.C. Wilson E.M. Wilkes E. Lee L.W. Norris R. Valdebran M. Kappa Opioid Agonists in the Treatment of Itch: Just Scratching the Surface? Itch 2023 8 e0072 10.1097/itx.0000000000000072 38099236 PMC10720604

100. Li X. Wan H. Dong P. Wang B. Zhang L. Hu Q. Zhang T. Feng J. He F. Bai C. Discovery of SHR0687, a Highly Potent and Peripheral Nervous System-Restricted KOR Agonist ACS Med. Chem. Lett. 2020 11 2151 2155 10.1021/acsmedchemlett.0c00287 33214823 PMC7667827

101. Chemicalbook Difelikefalin: Synthesis and Introduction ChemicalBook Inc. Albany, NY, USA 2024 Available online: https://www.chemicalbook.com/article/difelikefalin-synthesis-and-introduction.htm (accessed on 16 June 2026)

102. PharmaVoice FDA’s 2022 Drug Approvals Fall Short of Recent Norms Available online: https://www.pharmavoice.com/news/FDA-2022-drug-approvals-fell-by-the-numbers/640690/ (accessed on 2 February 2026)

103. Gandhy S.U. Casak S.J. Mushti S.L. Cheng J. Subramaniam S. Zhao H. Zhao M. Bi Y. Liu G. Fan J. FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements Clin. Cancer Res. 2023 29 4027 4031 10.1158/1078-0432.CCR-23-1042 37289037 PMC10592512

104. Ito S. Otsuki S. Ohsawa H. Hirano A. Kazuno H. Yamashita S. Egami K. Shibata Y. Yamamiya I. Yamashita F. Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use ACS Med. Chem. Lett. 2023 14 396 404 10.1021/acsmedchemlett.3c00006 37077386 PMC10108393

105. Benedetto Tiz D. Bagnoli L. Rosati O. Marini F. Santi C. Sancineto L. FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis Pharmaceutics 2022 14 2538 10.3390/pharmaceutics14112538 36432728 PMC9695118

106. Woods A.C. Norsworthy K.J. Choe M. Gehrke B.J. Chen H. Vallejo J. Pan L. Jiang X. Li H. Kraft J. FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation Clin. Cancer Res. 2025 31 12 17 10.1158/1078-0432.CCR-24-2196 39475462 PMC11703669

107. Cortes J.E. Olutasidenib: A Novel Mutant IDH1 Inhibitor for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Expert Rev. Hematol. 2024 17 211 221 10.1080/17474086.2024.2354486 38747392

108. Watts J.M. Shaw S.J. Jonas B.A. Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia Curr. Treat. Options Oncol. 2024 25 1345 1353 10.1007/s11864-024-01264-7 39406957 PMC11541360

109. Caravella J.A. Lin J. Diebold R.B. Campbell A.-M. Ericsson A. Gustafson G. Wang Z. Castro J. Clarke A. Gotur D. Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor J. Med. Chem. 2020 63 1612 1623 10.1021/acs.jmedchem.9b01423 31971798

110. Dhillon S. Adagrasib: First Approval Drugs 2023 83 275 285 10.1007/s40265-023-01839-y 36763320

111. De S.K. First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRAS G12C Mutation Curr. Med. Chem. 2024 31 266 272 10.2174/0929867330666230330122000 37005530

112. Lu Z. Chen C. Paymode D.J. Gan Y. Scattolin T. Roshandel S. Dong W. Yu S. Lemeune S. Snead D.R. Adagrasib’s Second-Generation Synthesis: Transitioning from Route Scouting to Optimization Org. Process Res. Dev. 2024 28 3128 3142 10.1021/acs.oprd.4c00024

113. Hoy S.M. Deucravacitinib: First Approval Drugs 2022 82 1671 1679 10.1007/s40265-022-01796-y 36401743 PMC9676857

114. Kalola U.K. Alberty A. Sheehy C. Deucravacitinib StatPearls StatPearls Publishing Treasure Island, FL, USA 2025 39163466

115. Raju L. Tiz D.B. Iles A. Košmrlj J. Jansen-van Vuuren R.D. Deuteration of Six-Membered N-Heteroarenes: Chemistry and Applications Chem.–Eur. J. 2025 31 e02659 10.1002/chem.202502659 41144923 PMC12671278

116. Effect of Deuterium Incorporation on Deucravacitinib Metabolism Available online: https://acs.digitellinc.com/p/s/effect-of-deuterium-incorporation-on-deucravacitinib-metabolism-605566 (accessed on 2 February 2026)

117. Profiles in Innovation—Discovery Moments: TYK2 Pseudokinase Inhibitor. MassBio Available online: https://www.massbio.org/news/recent-news/profiles-in-innovation-discovery-moments-tyk2-pseudokinase-inhibitor/ (accessed on 2 May 2026)

118. Zhuang-Yan A. Shirley M. Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults Drugs 2023 83 1613 1620 10.1007/s40265-023-01961-x 37991635

119. Fallah J. Agrawal S. Gittleman H. Fiero M.H. Subramaniam S. John C. Chen W. Ricks T.K. Niu G. Fotenos A. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer Clin. Cancer Res. 2023 29 1651 1657 10.1158/1078-0432.CCR-22-2875 36469000 PMC10159870

120. Ayyad A. Al-Horani R.A. Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile Gastroenterol. Insights 2023 14 420 430 10.3390/gastroent14040031 37873544 PMC10587779

121. Navarro V.J. Rossi S. Herrine S.K. Hepatic Cirrhosis Pharmacology and Therapeutics W.B. Saunders Philadelphia, PA, USA 2009 505 525

122. Scarpati G. Piazza O. Vasopressin vs Terlipressin in Treatment of Refractory Shock Transl. Med. UniSa 2013 5 22 27 23905079 PMC3728816

123. Du Y. Semghouli A. Wang Q. Mei H. Kiss L. Baecker D. Soloshonok V.A. Han J. FDA-Approved Drugs Featuring Macrocycles or Medium-Sized Rings Arch. Pharm. 2025 358 e2400890 10.1002/ardp.202400890 39865335 PMC11771699

124. Gounder M. Ratan R. Alcindor T. Schöffski P. Van Der Graaf W.T. Wilky B.A. Riedel R.F. Lim A. Smith L.M. Moody S. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors N. Engl. J. Med. 2023 388 898 912 10.1056/NEJMoa2210140 36884323 PMC11225596

125. Kummar S. Bui N. Messersmith W.A. Whiting J. Portnoy M. Lim A. Smith L.M. Nirogacestat-the Pathway to Approval of the First Treatment for Desmoid Tumors, a Rare Disease Ther. Adv. Rare Dis. 2025 6 26330040251317546 10.1177/26330040251317546 39944188 PMC11815814

126. Harrer D.C. Herrmann M. Vogelhuber M. Geis S. Mahr D. Niethard M. Keil F. Napodano G. Herr W. Grube M. Case Report: Nirogacestat Therapy Induces Rapid Response in a Patient with Refractory, Life-Threatening Desmoid Tumor Front. Oncol. 2025 15 1714475 10.3389/fonc.2025.1714475 41383518 PMC12689391

127. Shen D. Zhang Y. Li X. Bai Y. Xiong J. Seng D. Zhang Y. Liu H. Yuan S. Yang L. The Mechanism of Action and Chemical Synthesis of FDA Newly Approved Drug Molecules Drug Dev. Res. 2024 85 e22260 10.1002/ddr.22260 39254376

128. FDA Approval Summary: Capivasertib with Fulvestrant for HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer with PIK3CA/AKT1/PTEN Alterations—PMC Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC11588547/ (accessed on 4 February 2026)

129. Wang Y.-T. Yang P.-C. Zhang Y.-F. Sun J.-F. Synthesis and Clinical Application of New Drugs Approved by FDA in 2023 Eur. J. Med. Chem. 2024 265 116124 10.1016/j.ejmech.2024.116124 38183778

130. Li J. Wang Z. Shao Z. Fulvestrant in the Treatment of Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: A Review Cancer Med. 2019 8 1943 1957 10.1002/cam4.2095 31004402 PMC6536994

131. FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer—PubMed Available online: https://pubmed.ncbi.nlm.nih.gov/38875108/ (accessed on 4 February 2026) 10.1158/1078-0432.CCR-24-0949 PMC11326972 38875108

132. Barbato M.I. Barone A.K. Aungst S.L. Miller C.P. Ananthula S. Bi Y. Yang Y. Li X. Xiong Y. Fan J. FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery Clin. Cancer Res. 2025 31 4412 4418 10.1158/1078-0432.CCR-25-1333 40911439 PMC12416742

133. Tang H. Ouyang L. Sun Q. Repotrectinib (TPX-0005): A Macrocyclic ALK/ROS1/TRK Inhibitor for the Treatment of Nonsmall Cell Lung Cancer Drug Discovery Stories Elsevier Amsterdam, The Netherlands 2026 Volume 2 395 411

134. WIPO Search International and National Patent Collections WO2017007759 12 January 2017 Available online: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017007759 (accessed on 16 June 2026)

135. Fusco M.J. Casak S.J. Mushti S.L. Cheng J. Christmas B.J. Thompson M.D. Fu W. Wang H. Yoon M. Yang Y. FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer Clin. Cancer Res. 2024 30 3100 3104 10.1158/1078-0432.CCR-24-0281 38809262 PMC11293994

136. Zhang Y. Zou J.-Y. Wang Z. Wang Y. Fruquintinib: A Novel Antivascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor for the Treatment of Metastatic Colorectal Cancer Cancer Manag. Res. 2019 11 7787 7803 10.2147/CMAR.S215533 31496821 PMC6701622

137. Syaj S. Saeed A. Profile of Fruquintinib in the Management of Advanced Refractory Metastatic Colorectal Cancer: Design, Development and Potential Place in Therapy Drug Des. Dev. Ther. 2024 18 5203 5210 10.2147/DDDT.S388577 39568782 PMC11577260

138. Xie Y. Tang S. Qin Z. Yang C. Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview Pharmaceuticals 2025 18 280 10.3390/ph18020280 40006092 PMC11859084

139. Xu D. Zeng S. Qiu W. Wang G. Qin Z. Liu Y. Zhou S. Zhang Z. Chang W. Feng Q. Fruquintinib in Refractory Metastatic Colorectal Cancer: A Multicenter Real-World Study ESMO Open 2024 9 103702 10.1016/j.esmoop.2024.103702 39395266 PMC11693424

140. Modi S.J. Kulkarni V.M. Exploration of Structural Requirements for the Inhibition of VEGFR-2 Tyrosine Kinase: Binding Site Analysis of Type II, ‘DFG-out’ Inhibitors J. Biomol. Struct. Dyn. 2022 40 5712 5727 10.1080/07391102.2021.1872417 33459187

141. Flick A.C. Leverett C.A. Ding H.X. McInturff E. Fink S.J. Helal C.J. DeForest J.C. Morse P.D. Mahapatra S. O’Donnell C.J. Synthetic Approaches to New Drugs Approved During 2018 J. Med. Chem. 2020 63 10652 10704 10.1021/acs.jmedchem.0c00345 32338902

142. Jehanzeb M. Iqbal U. Farhat N. Waseem R. Shahzad M. Eljack M.M.F. FDA Greenlights Momelotinib (Ojjaara) as the Exclusive Treatment for Myelofibrosis Patients Battling Anemia Ann. Med. Surg. 2024 86 6916 6917 10.1097/MS9.0000000000002690 39649856 PMC11623888

143. Sastow D. Tremblay D. Emerging Treatment Options for Myelofibrosis: Focus on Anemia Ther. Clin. Risk Manag. 2023 19 535 547 10.2147/TCRM.S386802 37404252 PMC10315142

144. Naymagon L. Mascarenhas J. Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies HemaSphere 2017 1 e1 10.1097/HS9.0000000000000001 31723730 PMC6745971

145. Little S.E. Lotilaner—A Novel Systemic Tick and Flea Control Product for Dogs Parasit. Vectors 2017 10 539 10.1186/s13071-017-2471-3 29089062 PMC5664799

146. Syed Y.Y. Lotilaner Ophthalmic Solution 0.25%: First Approval Drugs 2023 83 1537 1541 10.1007/s40265-023-01947-9 37843754 PMC10624734

147. Lasmar P.V.F. Murphy M. Nanchen S. Drake J. Coumendouros K. Borges D.A. De Oliveira P.C. Scott F.B. Laboratory Evaluation of the Efficacy of Lotilaner (Credelio TM ) Against Amblyomma cajennense (Sensu Lato) Infestations of Dogs Parasit. Vectors 2018 11 537 10.1186/s13071-018-3116-x 30285898 PMC6171179

148. Rufener L. Danelli V. Bertrand D. Sager H. The Novel Isoxazoline Ectoparasiticide Lotilaner (Credelio TM ): A Non-Competitive Antagonist Specific to Invertebrates γ-Aminobutyric Acid-Gated Chloride Channels (GABACls) Parasit. Vectors 2017 10 530 10.1186/s13071-017-2470-4 29089046 PMC5664438

149. Blair H.A. Ritlecitinib: First Approval Drugs 2023 83 1315 1321 10.1007/s40265-023-01928-y 37556041 PMC10556173

150. Fung S. Shirley M. Baricitinib: A Review in Severe Alopecia Areata Am. J. Clin. Dermatol. 2023 24 661 668 10.1007/s40257-023-00799-z 37326792

151. King B. Zhang X. Harcha W.G. Szepietowski J.C. Shapiro J. Lynde C. Mesinkovska N.A. Zwillich S.H. Napatalung L. Wajsbrot D. Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial Lancet 2023 401 1518 1529 10.1016/S0140-6736(23)00222-2 37062298

152. Tao Y. McWilliams J.C. Wiglesworth K.E. Girard K.P. Makowski T.M. Sach N.W. Mustakis J.G. Mehta R. Trujillo J.I. Chen X. Process Development and Scale up of a Selective JAK3 Covalent Inhibitor PF-06651600 Org. Process Res. Dev. 2019 23 1872 1880 10.1021/acs.oprd.9b00198

153. Bhatia A. Preiss A.J. Xiao X. Brannock M.D. Alexander G.C. Chew R.F. Davis H. Fitzgerald M. Hill E. Kelly E.P. Effect of Nirmatrelvir/Ritonavir (Paxlovid) on Hospitalization Among Adults with COVID-19: An Electronic Health Record-Based Target Trial Emulation from N3C PLoS Med. 2025 22 e1004493 10.1371/journal.pmed.1004493 39823513 PMC11790232

154. Lewnard J.A. McLaughlin J.M. Malden D. Hong V. Puzniak L. Ackerson B.K. Lewin B.J. Kim J.S. Shaw S.F. Takhar H. Effectiveness of Nirmatrelvir–Ritonavir in Preventing Hospital Admissions and Deaths in People with COVID-19: A Cohort Study in a Large US Health-Care System Lancet Infect. Dis. 2023 23 806 815 10.1016/S1473-3099(23)00118-4 36933565 PMC10081864

155. Rai D.K. Yurgelonis I. McMonagle P. Rothan H.A. Hao L. Gribenko A. Titova E. Kreiswirth B. White K.M. Zhu Y. Nirmatrelvir, an Orally Active Mpro Inhibitor, Is a Potent Inhibitor of SARS-CoV-2 Variants of Concern bioRxiv 2022 10.1101/2022.01.17.476644

156. Duveau D.Y. Thomas C.J. The Remarkable Selectivity of Nirmatrelvir ACS Pharmacol. Transl. Sci. 2022 5 445 447 10.1021/acsptsci.2c00065 35702394 PMC9128007

157. Galli M. Migliano F. Fasano V. Silvani A. Passarella D. Citarella A. Nirmatrelvir: From Discovery to Modern and Alternative Synthetic Approaches Processes 2024 12 1242 10.3390/pr12061242

158. Pereira M. Vale N. Ritonavir’s Evolving Role: A Journey from Antiretroviral Therapy to Broader Medical Applications Curr. Oncol. 2024 31 6032 6049 10.3390/curroncol31100450 39451754 PMC11505664

159. Hung Y.-P. Lee J.-C. Chiu C.-W. Lee C.-C. Tsai P.-J. Hsu I.-L. Ko W.-C. Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark? Antibiotics 2022 11 220 10.3390/antibiotics11020220 35203821 PMC8868411

160. Algera R.F. Allais C. Baldwin A.F. Becirovic H. Bowles P. Brown A.R. Buske J.M. Clarke H.J. Do N.M. Doyle K. Synthesis of Nirmatrelvir: Development of an Efficient, Scalable Process to Generate the Western Fragment Org. Process Res. Dev. 2023 27 2240 2249 10.1021/acs.oprd.3c00249

161. Bege M. Borbás A. The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19 Pharmaceutics 2024 16 217 10.3390/pharmaceutics16020217 38399271 PMC10891713

162. Elendu C. Okahia T.W. Blewusi G.S. Meduoye O.O.M. Ogelle E.C. Egbo A.R. Nwankwo V.C. Amaefule K.C. Emechebe S.L. Mohamed A.A. FDA Approves Veozah (Fezolinetant) for Menopausal Symptoms: A New Nonhormonal Option Ann. Med. Surg. 2025 87 5373 5377 10.1097/MS9.0000000000003670 40901162 PMC12401328

163. Nappi R.E. Cagnacci A. Di Carlo C. Genazzani A.D. Villa P. Simoncini T. Targeting Vasomotor Symptoms with the New Drug Fezolinetant—An Expert Overview Gynecol. Endocrinol. 2025 41 2526560 10.1080/09513590.2025.2526560 40627615

164. Romanelli M.N. Braconi L. Gabellini A. Manetti D. Marotta G. Teodori E. Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011–2023 Molecules 2023 29 68 10.3390/molecules29010068 38202651 PMC10780301

165. Dhillon S. Zavegepant: First Approval Drugs 2023 83 825 831 10.1007/s40265-023-01885-6 37227596 PMC10209931

166. Fan H. Wadolowski J. Shan R. Contrera G.J. Polomoff C.M. Clinical Evaluation of Zavegepant for the Acute Treatment of Migraine J. Manag. Care Spec. Pharm. 2025 31 598 602 10.18553/jmcp.2025.31.6.598 40443004 PMC12123197

167. Lee A. Omaveloxolone: First Approval Drugs 2023 83 725 729 10.1007/s40265-023-01874-9 37155124

168. Pilotto F. Chellapandi D.M. Puccio H. Omaveloxolone: A Groundbreaking Milestone as the First FDA-Approved Drug for Friedreich Ataxia Trends Mol. Med. 2024 30 117 125 10.1016/j.molmed.2023.12.002 38272714

169. Lynch D.R. Chin M.P. Delatycki M.B. Subramony S.H. Corti M. Hoyle J.C. Boesch S. Nachbauer W. Mariotti C. Mathews K.D. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia ( MOXIe Study) Ann. Neurol. 2021 89 212 225 10.1002/ana.25934 33068037 PMC7894504

170. Cordaro M. Neri G. Ansari S.A.M.K. Buccheri R. Scala A. Piperno A. Synthesis and Biological Profile of Omaveloxolone: The Cornerstone for Friedreich Ataxia Treatment Int. J. Mol. Sci. 2025 26 9747 10.3390/ijms26199747 41097010 PMC12524927

171. Haider M.U. Furqan M. Mehmood Q. Daprodustat: A Potential Game-Changer in Renal Anemia Therapy—A Perspective Front. Pharmacol. 2023 14 1249492 10.3389/fphar.2023.1249492 37637409 PMC10449327

172. Manda A. Basu D. Sankar Reddy P. Muttabattula P. Komati S.K. Nair R. Senadi G.C. Maruthapillai A. Bandichhor R. Novel and Cost-Effective Manufacturing Process Development of Daprodustat Org. Process Res. Dev. 2025 29 953 963 10.1021/acs.oprd.5c00041

173. Telaraja D. Kasamon Y.L. Collazo J.S. Leong R. Wang K. Li P. Dahmane E. Yang Y. Earp J. Grimstein M. FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma Clin. Cancer Res. 2024 30 17 22 10.1158/1078-0432.CCR-23-1272 37624619 PMC10841293

174. Shah N.N. Zinzani P.L. Wang M. Nasta S.D. Lech-Maranda E. Ogawa Y. Fakhri B. Kuss B. Miyashita K. Patel K. Pirtobrutinib, a Highly Selective, Noncovalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study Blood Adv. 2025 9 5954 5964 10.1182/bloodadvances.2024014975 40845254 PMC12686794

175. Ibrahim S. Pham N. Sahni A. Sekeres S. Cool A. Taylor J. Coombs C.C. Pirtobrutinib in the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Future Oncol. 2025 21 3435 3445 10.1080/14796694.2025.2567834 41042631 PMC12582124

176. Keam S.J. Trofinetide: First Approval Drugs 2023 83 819 824 10.1007/s40265-023-01883-8 37191913

177. Hudu S.A. Elmigdadi F. Qtaitat A.A. Almehmadi M. Alsaiari A.A. Allahyani M. Aljuaid A. Salih M. Alghamdi A. Alrofaidi M.A. Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need J. Clin. Med. 2023 12 5114 10.3390/jcm12155114 37568516 PMC10420089

178. Virginia T.P. Pharmacotherapy Innovation for Rett Syndrome Available online: https://www.uspharmacist.com/article/pharmacotherapy-innovation-for-rett-syndrome (accessed on 6 February 2026)

179. Mughal Z.U.N. Ahmed B. Rangwala B.S. Rangwala H.S. Fatima H. Ali M. Farah A.A. Trofinetide Receives FDA Approval as First Drug for Rett Syndrome Ann. Med. Surg. 2024 86 2382 2385 10.1097/MS9.0000000000001896 38694380 PMC11060233

180. Feng X. Dong Y. Guo C. Lu J. Xu Z. Bian J. Peng W. Luo T. Feng J. Design, Synthesis and Evaluation of Trofinetide Prodrug Based on Diketopiperazine Strategy Bioorg. Med. Chem. 2026 137 118633 10.1016/j.bmc.2026.118633 41850142

181. Syed Y.Y. Rezafungin: First Approval Drugs 2023 83 833 840 10.1007/s40265-023-01891-8 37212966

182. Susan V. Lang M. Sabou M. Bourel-Bonnet L. Antifungal Drugs for the Treatment of Invasive Fungal Infections—A Limited Therapeutic Toolbox Facing Growing Resistances Pharmaceuticals 2025 18 1220 10.3390/ph18081220 40872609 PMC12389444

183. Hetta H.F. Melhem T. Aljohani H.M. Salama A. Ahmed R. Elfadil H. Alanazi F.E. Ramadan Y.N. Battah B. Rottura M. Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways Pharmaceuticals 2025 18 364 10.3390/ph18030364 40143141 PMC11944814

184. Garcia-Effron G. Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins J. Fungi 2020 6 262 10.3390/jof6040262 33139650 PMC7711656

185. Shao L. Li J. Liu A. Chang Q. Lin H. Chen D. Efficient Bioconversion of Echinocandin B to Its Nucleus by Overexpression of Deacylase Genes in Different Host Strains Appl. Environ. Microbiol. 2013 79 1126 1133 10.1128/AEM.02792-12 23220968 PMC3568618

186. Hoppe J.E. Kasi A.S. Pittman J.E. Jensen R. Thia L.P. Robinson P. Tirakitsoontorn P. Ramsey B. Mall M.A. Taylor-Cousar J.L. Vanzacaftor–Tezacaftor–Deutivacaftor for Children Aged 6–11 Years with Cystic Fibrosis (RIDGELINE Trial VX21-121-105): An Analysis from a Single-Arm, Phase 3 Trial Lancet Respir. Med. 2025 13 244 255 10.1016/S2213-2600(24)00407-7 39756425 PMC12126198

187. Mullard A. FDA Approves Next-Generation Triple Therapy for Cystic Fibrosis Nat. Rev. Drug Discov. 2025 24 83 10.1038/d41573-025-00008-y 39806010

188. Keating C. Yonker L.M. Vermeulen F. Prais D. Linnemann R.W. Trimble A. Kotsimbos T. Mermis J. Braun A.T. O’Carroll M. Vanzacaftor–Tezacaftor–Deutivacaftor versus Elexacaftor–Tezacaftor–Ivacaftor in Individuals with Cystic Fibrosis Aged 12 Years and Older (SKYLINE Trials VX20-121-102 and VX20-121-103): Results from Two Randomised, Active-Controlled, Phase 3 Trials Lancet Respir. Med. 2025 13 256 271 10.1016/S2213-2600(24)00411-9 39756424 PMC12184100

189. Baroni D. Unraveling the Mechanism of Action, Binding Sites, and Therapeutic Advances of CFTR Modulators: A Narrative Review Curr. Issues Mol. Biol. 2025 47 119 10.3390/cimb47020119 39996840 PMC11854517

190. Hussain K. Karhana S. Garg A. Khan M.A. Efficacy of Trikafta (ELX/TEZ/IVA) & Symdeko (TEZ/IVA) in Treating Cystic Fibrosis with F508del Allele: A Systematic Review and Meta-Analysis Thorac. Res. Pract. 2025 26 248 259 10.4274/ThoracResPract.2025.2025-1-1 40336353 PMC12365565

191. Middleton P.G. Mall M.A. Dřevínek P. Lands L.C. McKone E.F. Polineni D. Ramsey B.W. Taylor-Cousar J.L. Tullis E. Vermeulen F. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele N. Engl. J. Med. 2019 381 1809 1819 10.1056/NEJMoa1908639 31697873 PMC7282384

192. Uluer A.Z. MacGregor G. Azevedo P. Indihar V. Keating C. Mall M.A. McKone E.F. Ramsey B.W. Rowe S.M. Taylor-Cousar J.L. Safety and Efficacy of Vanzacaftor–Tezacaftor–Deutivacaftor in Adults with Cystic Fibrosis: Randomised, Double-Blind, Controlled, Phase 2 Trials Lancet Respir. Med. 2023 11 550 562 10.1016/S2213-2600(22)00504-5 36842446 PMC12815409

193. Chemicalbook The Synthesis Method of Tezacaftor ChemicalBook Inc. Albany, NY, USA 2024 Available online: https://www.chemicalbook.com/article/the-synthesis-method-of-tezacaftor.htm (accessed on 16 June 2026)

194. Wang Z. Sun X. Sun M. Wang C. Yang L. Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024 Pharmaceuticals 2025 18 729 10.3390/ph18050729 40430547 PMC12114780

195. Ensartinib LiverTox: Clinical and Research Information on Drug-Induced Liver Injury National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD, USA 2012 31643176

196. Yadav V. Reang J. Vinita Sharma P.C. Sharma K. Kumar D. Tonk R.K. Insight into Systematic Development of ALK (Anaplastic Lymphoma Kinase) Inhibitors towards NSCLC Treatment Eur. J. Med. Chem. Rep. 2024 10 100142 10.1016/j.ejmcr.2024.100142

197. Dooley M. Jarvis B. Iomeprol: A Review of Its Use as a Contrast Medium Drugs 2000 59 1169 1186 10.2165/00003495-200059050-00013 10852647

198. Peress L. Kaitzberg A. Silberstein E. Shelef I. Retchkiman M. Comparison of Iomeprol-400, Ultravist-370, and Omnipaque-350 in Preoperative Computed Tomography for Visualizing the Deep Inferior Epigastric Perforators Plast. Reconstr. Surg.-Glob. Open 2025 13 e6670 10.1097/GOX.0000000000006670 40182304 PMC11964380

199. Zou P. Luo S. Xie M. Liu Y. He Y. Wang H. Iomeprol Preparation Method CN102363600B 17 July 2013

200. Arellano M.L. Thirman M.J. DiPersio J.F. Heiblig M. Stein E.M. Schuh A.C. Žučenka A. De Botton S. Grove C.S. Mannis G.N. Menin Inhibition with Revumenib for NPM1 -Mutated Relapsed or Refractory Acute Myeloid Leukemia: The AUGMENT-101 Study Blood 2025 146 1065 1077 10.1182/blood.2025028357 40332046 PMC12824668

201. Salman M.Y. Stein E.M. Revumenib for Patients with Acute Leukemia: A New Tool for Differentiation Therapy Haematologica 2024 109 3488 3495 10.3324/haematol.2022.282621 39086307 PMC11532683

202. Heikamp E.B. Armstrong S.A. Revumenib Revises the Treatment Landscape for KMT2A -r Leukemia J. Clin. Oncol. 2025 43 85 88 10.1200/JCO-24-01265 39509656 PMC11771282

203. Aslam A. Ahmed M. Mughram M.H.A. Mahmood M. Basheer S. Hussain R. Eiman E. Sanaullah M. Raza H. Saeed A. Sulfonamides as a Promising Scaffold in Drug Discovery: An Insightful Review on FDA-Approved Molecules, Synthesis Strategy, Medical Indication, and Their Binding Mode Chem. Biodivers. 2025 22 e202403434 10.1002/cbdv.202403434 40035790

204. The Medical Letter, Inc. Sulopenem Etzadroxil/Probenecid (Orlynvah) for Uncomplicated UTIs Med. Lett. Drugs Ther. 2025 67 179 180 10.58347/tml.2025.1741b 41190906

205. Shahid K. Shahid S.R. Khalid M. Waafira A. Redefining uUTI Therapy: Orlynvah as a Promising Oral Alternative (Sulopenem Etzadroxil and Probenecid) Ann. Med. Surg. 2025 87 6946 6948 10.1097/MS9.0000000000003933 41180696 PMC12577795

206. Ocheretyaner E. Melgar K. Kalabalik-Hoganson J. Sulopenem Etzadroxil and Probenecid: A Drug Review of a Novel Oral Penem Active against ESBL-Producing Bacteria Am. J. Health Syst. Pharm. 2025 83 e6 e11 10.1093/ajhp/zxaf220 40826193

207. Rusu A. Oancea O.-L. Donici E. Uncu L. Recent Developments in Penem Antibiotics: Structural and Therapeutic Perspectives Molecules 2025 30 2126 10.3390/molecules30102126 40430299 PMC12113772

208. D.A.M.C. Sulopenem. New Drug Approvals 2025 Available online: https://newdrugapprovals.org/2025/04/23/sulopenem/ (accessed on 2 May 2026)

209. Blair H.A. Inavolisib: First Approval Drugs 2025 85 271 278 10.1007/s40265-024-02136-y 39873916

210. Han J. Wzorek A. Dhawan G. Zhang W. Sorochinsky A. Baecker D. Ono T. Klika K. Soloshonok V. New Drugs on the Pharmaceutical Market Containing Fluorine And Residues of Tailor-Made Amino Acids Ukr. Chem. J. 2024 90 31 56 10.33609/2708-129X.90.9.2024.31-56

211. Rodriguez-Gil J.L. Smith W.E. Chang I.J. Mendelsohn B.A. Arimoclomol and Levacetylleucine for the Treatment of Neurologic Manifestations of Niemann-Pick Disease Type C: A Therapeutics Bulletin of the American College of Medical Genetics and Genomics (ACMG) Genet. Med. Open 2025 3 103462 10.1016/j.gimo.2025.103462 41542346 PMC12800820

212. Al Musaimi O. AlShaer D. De La Torre B.G. Albericio F. 2024 FDA TIDES (Peptides and Oligonucleotides) Harvest Pharmaceuticals 2025 18 291 10.3390/ph18030291 40143070 PMC11945313

213. Davis L.C. Braine R. Churchill G.C. Factor M. Fields T. Patterson M. Platt F. Strupp M. Galione A. N-Acetyl-L-Leucine (Levacetylleucine) Normalizes Transcription Factor EB (TFEB) Activity by Stereospecific Bidirectional Modulation bioRxiv 2025 10.64898/2025.11.30.691375 PMC13378962 42467639

214. Shah D. Shah D. Ndandji S. Kar S. Lazertinib: A Novel EGFR-TKI Therapy for Non-Small Cell Lung Cancer Expert Opin. Drug Metab. Toxicol. 2025 21 789 800 10.1080/17425255.2025.2507404 40372786

215. Hong M.H. Choi Y.J. Ahn H.K. Lim S.M. Keam B. Kim D.-W. Kim T.M. Youk J. Kim Y.J. Hwang S. Lazertinib in EGFR -Variant Non–Small Cell Lung Cancer with CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial JAMA Oncol. 2024 10 1342 1351 10.1001/jamaoncol.2024.2640 39145962 PMC11327907

216. Patel K.B. Heppner D.E. Lazertinib: Breaking the Mold of Third-Generation EGFR Inhibitors RSC Med. Chem. 2025 16 1049 1066 10.1039/D4MD00800F 39867588 PMC11758113

217. Oh S.-H. Khoo J.-H. Lim J.-C. Lee S.-R. Ju H. Shin W.-S. Park D.-G. Park S.-M. Hwang Y.-A. Improved Process for Preparing Aminopyrimidine Derivatives WO2019022485A1 31 January 2019

218. Dhillon S. Tovorafenib: First Approval Drugs 2024 84 985 993 10.1007/s40265-024-02069-6 38967715

219. Zhang T. Xu B. Tang F. He Z. Zhou J. Type II RAF Inhibitor Tovorafenib for the Treatment of Pediatric Low-Grade Glioma Expert Rev. Clin. Pharmacol. 2024 17 999 1008 10.1080/17512433.2024.2418405 39412085

220. Singh S. Bradford D. Chatterjee S. Li X. Aungst S.L. Skinner A.M. Miller C.P. Kim-McOlash S. Fourie Zirkelbach J. Xiong Y. FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma Clin. Cancer Res. 2025 31 1383 1389 10.1158/1078-0432.CCR-24-3439 39808502 PMC11996598

221. Liu H.-N. Zhu Y. Chi Y. Sun F.-F. Shan L.-S. Wang Y.-T. Dai B. Synthetic Approaches and Application of Representative Clinically Approved Fluorine-Enriched Anti-Cancer Medications Eur. J. Med. Chem. 2024 276 116722 10.1016/j.ejmech.2024.116722 39079309

222. Zimmerman J. Giuliano C. Kale-Pradhan P.B. Ceftobiprole Medocaril: A New Fifth-Generation Cephalosporin Ann. Pharmacother. 2025 59 657 665 10.1177/10600280241293773 39644134

223. Méndez R. Latorre A. González-Jiménez P. Ceftobiprole Medocaril Rev. Esp. Quimioter. 2022 35 25 27 10.37201/req/s01.05.2022 35488820 PMC9106187

224. Conti P. Lazzaro L.M. Longo F. Lenzo F. Giardina A. Fortuna S.A. Stefani S. Campanile F. Unveiling the Relationship between Ceftobiprole and High-Molecular-Mass (HMM) Penicillin-Binding Proteins (PBPs) in Enterococcus Faecalis Antibiotics 2024 13 65 10.3390/antibiotics13010065 38247624 PMC10812503

225. ARD Profile Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788 Drugs R D 2006 7 305 311 10.2165/00126839-200607050-00003 16922591

226. Xu B. Zhou J. Oral Complement Factor D Inhibitor Danicopan for Paroxysmal Nocturnal Hemoglobinuria Expert Rev. Clin. Pharmacol. 2024 17 857 864 10.1080/17512433.2024.2403638 39258779

227. Gadhachanda V.R. Wiles J.A. Podos S.D. Boyer D. Thanassi J. Patel D. Zhao Y. Wang L. Huang M. First-in-Class Clinically Investigated Oral Factor D Inhibitors for the Treatment of Complement-Mediated Diseases Pharm. Res. 2025 42 1119 1131 10.1007/s11095-025-03882-8 40562872

228. Nangaku M. Farag Y.M.K. deGoma E. Luo W. Vargo D. Khawaja Z. Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, for Treatment of Anemia of Chronic Kidney Disease: Two Randomized Phase 2 Trials in Japanese Patients Nephrol. Dial. Transplant. 2021 36 1244 1252 10.1093/ndt/gfaa060 32719868

229. Zuk A. Si Z. Loi S. Bommegowda S. Hoivik D. Danthi S. Molnar G. Csizmadia V. Rabinowitz M. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia J. Pharmacol. Exp. Ther. 2022 383 11 24 10.1124/jpet.122.001126 35926869

230. Lin B. Kou J. Wu S. Cai X. Xiao Q. Li Y. Hu J. Li J. Wang Z. Development of a Robust and Scalable Process for the Large-Scale Preparation of Vadadustat Org. Process Res. Dev. 2021 25 960 968 10.1021/acs.oprd.1c00004

231. Guirguis E. Dougherty J. Thornby K. Grace Y. Mack K. Resmetirom: The First Food and Drug Administration–Approved Medication for Nonalcoholic Steatohepatitis (NASH) Ann. Pharmacother. 2025 59 162 173 10.1177/10600280241259528 38887011

232. Karim G. Bansal M.B. Resmetirom: An Orally Administered, Small-Molecule, Liver-Directed, β-Selective THR Agonist for the Treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis Eur. Endocrinol. 2023 19 60 70 10.17925/EE.2023.19.1.60 37313239 PMC10258622

233. Tiwari A. Sharma A. Kumar H. Gupta V. Deshpande V. Mupparaju J.S. Mishra T. Bharadwaj H.R. Dahiya D.S. Jain V. Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier Biomedicines 2025 13 2079 10.3390/biomedicines13092079 41007643 PMC12467964

234. Resmetirom: A Promising Treatment for Non-Alcoholic Steatohepatitis—American Journal of Pharmacotherapy and Pharmaceutical Sciences Available online: https://ajpps.org/resmetirom-a-promising-treatment-for-non-alcoholic-steatohepatitis/ (accessed on 13 February 2026)

235. Cui Y. Zhang J. Liu S. Zhao Z. Shan M. Jiang N. Zhai X. An Alternate and Efficient Synthetic Process for a Metabolic Dysfunction-Associated Steatohepatitis Drug: Resmetirom Org. Process Res. Dev. 2025 29 2230 2237 10.1021/acs.oprd.5c00149

236. Keam S.J. Cefepime/Enmetazobactam: First Approval Drugs 2024 84 737 744 10.1007/s40265-024-02035-2 38761353

237. Bhowmick T. Canton R. Pea F. Quevedo J. Santerre Henriksen A. Timsit J.-F. Kaye K.S. Cefepime-Enmetazobactam: First Approved Cefepime-β- Lactamase Inhibitor Combination for Multi-Drug Resistant Enterobacterales Future Microbiol. 2025 20 277 286 10.1080/17460913.2025.2468112 40007489 PMC11938971

238. Carcione D. Brigante G. Carducci A. Intra J. Ambretti S. Campanile F. Arcari G. Mancini N. Cattaneo D. Gona F. Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics Pharmaceuticals 2026 19 283 10.3390/ph19020283 41754823 PMC12944649

239. Kaye K.S. Belley A. Barth P. Lahlou O. Knechtle P. Motta P. Velicitat P. Effect of Cefepime/Enmetazobactam vs. Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients with Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial JAMA 2022 328 1304 1314 10.1001/jama.2022.17034 36194218 PMC9533186

240. Exblifep (Cefepime and Enmetazobactam for Injection): Side Effects, Uses, Dosage, Interactions, Warnings Available online: https://www.rxlist.com/exblifep-drug.htm (accessed on 16 February 2026)

241. Sargianou M. Stathopoulos P. Vrysis C. Tzvetanova I.D. Falagas M.E. New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Pathogens 2025 14 307 10.3390/pathogens14040307 40333039 PMC12029989

242. Darlow C.A. Hope W. Dubey V. Cefepime/Enmetazobactam: A Microbiological, Pharmacokinetic, Pharmacodynamic, and Clinical Evaluation Expert Opin. Drug Metab. Toxicol. 2025 21 115 123 10.1080/17425255.2024.2427310 39508805

243. Niu Z.-X. Wang Y.-T. Zhang S.-N. Li Y. Chen X.-B. Wang S.-Q. Liu H.-M. Application and Synthesis of Thiazole Ring in Clinically Approved Drugs Eur. J. Med. Chem. 2023 250 115172 10.1016/j.ejmech.2023.115172 36758304

244. De La Torre B.G. Albericio F. The Pharmaceutical Industry in 2025: An Analysis of FDA Drug Approvals from the Perspective of Molecules Molecules 2026 31 419 10.3390/molecules31030419 41683395 PMC12898419

245. McCormick B. Rilzabrutinib Becomes First FDA-Approved BTK Inhibitor for ITP|AJMC Available online: https://www.ajmc.com/view/rilzabrutinib-becomes-first-fda-approved-btk-inhibitor-for-itp (accessed on 21 September 2025)

246. Jan M. Qazi K. Noor A. Naveed M. Khalid M. Waafira A. A New Era in Chronic Spontaneous Urticaria: FDA Approval of the Oral BTK Inhibitor Remibrutinib Ann. Med. Surg. 2026 88 974 975 10.1097/MS9.0000000000004298 41497012 PMC12768181

247. Hujjat S.F.Z. Chandani H.K. Khan M.S. Chandani D.K. Mahmoud A. Bruton’s Tyrosine Kinase Inhibition in ITP: Wayrilz (Rilzabrutinib) as a Disease-Modifying Strategy Ann. Med. Surg. 2025 87 7907 7909 10.1097/MS9.0000000000004164 41377239 PMC12688840

248. Labanca C. Martino E.A. Vigna E. Bruzzese A. Mendicino F. Caridà G. Lucia E. Olivito V. Manicardi V. Amodio N. Rilzabrutinib for the Treatment of Immune Thrombocytopenia Eur. J. Haematol. 2025 115 4 15 10.1111/ejh.14425 40222822 PMC12134720

249. Kuter D.J. Ghanima W. Evaluating Rilzabrutinib in the Treatment of Immune Thrombocytopenia Immunotherapy 2025 17 767 782 10.1080/1750743X.2025.2545170 40788289 PMC12427540

250. Ahmadinia M. Askarzade A. Afsharara H. Gholizadeh Niari B. Jamali F. Farasatinasab M. Translational Immunothrombosis in Autoimmune Heparin-Induced Thrombocytopenia: Targeting the FcγRIIa–Syk–BTK and Complement Pathways Clin. Exp. Med. 2026 26 151 10.1007/s10238-026-02048-z 41689663 PMC12909329

251. Brullo C. Villa C. Tasso B. Russo E. Spallarossa A. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective Int. J. Mol. Sci. 2021 22 7641 10.3390/ijms22147641 34299259 PMC8303217

252. Sousa B.B. De Almeida C.R. Barahona A.F. Lopes R. Martins-Logrado A. Cavaco M. Neves V. Carvalho L.A.R. Labão-Almeida C. Coelho A.R. Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors ACS Pharmacol. Transl. Sci. 2022 5 1156 1168 10.1021/acsptsci.2c00163 36407952 PMC9667546

253. Benedetto Tiz D. D’Alì M. Iraci N. Santi C. Sancineto L. Halogen-Containing Drugs in 2025: A Record Year for the Therapeutic Use and Synthesis of FDA-Approved Small Molecules Biomolecules 2026 16 381 10.3390/biom16030381 41897316 PMC13023470

254. Gimeno R. Ribas-Llauradó C. Pesque D. Andrades E. Cenni B. Ambros B. Pujol R. Giménez-Arnau A.M. Remibrutinib Inhibits Hives Effector Cells Stimulated by Serum from Chronic Urticaria Patients Independently of FcεR1 Expression Level and Omalizumab Clinical Response Clin. Transl. Allergy 2023 13 e12227 10.1002/clt2.12227 36973953 PMC9985467

255. Kaul M. End P. Cabanski M. Schuhler C. Jakab A. Kistowska M. Kinhikar A. Maiolica A. Sinn A. Fuhr R. Remibrutinib (LOU064): A Selective Potent Oral BTK Inhibitor with Promising Clinical Safety and Pharmacodynamics in a Randomized Phase I Trial Clin. Transl. Sci. 2021 14 1756 1768 10.1111/cts.13005 33834628 PMC8504815

256. Fung S. Remibrutinib: First Approval Drugs 2026 86 403 410 10.1007/s40265-025-02281-y 41559488

257. Hartman J.J. Hwee D.T. Robert-Paganin J. Chuang C. Chin E.R. Edell S. Lee K.H. Madhvani R. Paliwal P. Pernier J. Aficamten Is a Small-Molecule Cardiac Myosin Inhibitor Designed to Treat Hypertrophic Cardiomyopathy Nat. Cardiovasc. Res. 2024 3 1003 1016 10.1038/s44161-024-00505-0 39196032 PMC11358156

258. Mohran S. Kooiker K.B. Naim A. Pilagov M. Asencio A. Turner K.L. Ma W. Flint G. Jiang S. Zhao J. Myosin Modulator Aficamten Inhibits Force in Cardiac Muscle by Altering Myosin’s Biochemical Activity without Changing Thick Filament Structure bioRxiv 2025 10.1101/2025.05.14.654110 41421020 PMC12794416

259. Chuang C. Collibee S. Ashcraft L. Wang W. Vander Wal M. Wang X. Hwee D.T. Wu Y. Wang J. Chin E.R. Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy J. Med. Chem. 2021 64 14142 14152 10.1021/acs.jmedchem.1c01290 34606259

260. Siegel F. Siegel S. Kotýnková K. Karsli Uzunbas G. Korr D. Tomono H. Andersen S. Denney D. Berger M. Schulze V.K. Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer Cancer Discov. 2026 16 81 94 10.1158/2159-8290.CD-25-0605 41090369 PMC12793832

261. Le X. Kim T.M. Loong H.H. Prelaj A. Goh B.C. Li L. Fang Y. Lu S. Dong X. Wu L. Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer N. Engl. J. Med. 2025 393 1819 1832 10.1056/NEJMoa2511065 41104928

262. Trillo Aliaga P. Spitaleri G. Attili I. Corvaja C. Battaiotto E. Angelopoulos P.A. Del Signore E. Passaro A. De Marinis F. HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top Molecules 2025 30 2645 10.3390/molecules30122645 40572608 PMC12195848

263. FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause|AJMC Available online: https://www.ajmc.com/view/fda-approves-elinzanetant-a-hormone-free-option-for-hot-flashes-in-menopause (accessed on 25 October 2025)

264. Hager M. Goldstein T. Fitz V. Ott J. Elinzanetant, a New Combined Neurokinin-1/-3 Receptor Antagonist for the Treatment of Postmenopausal Vasomotor Symptoms Expert Opin. Pharmacother. 2024 25 783 789 10.1080/14656566.2024.2358131 38869992

265. Pawsey S. Mills E.G. Ballantyne E. Donaldson K. Kerr M. Trower M. Dhillo W.S. Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women J. Clin. Endocrinol. Metab. 2021 106 e3221 e3234 10.1210/clinem/dgab108 33624806 PMC8277204

266. Simon J.A. Anderson R.A. Ballantyne E. Bolognese J. Caetano C. Joffe H. Kerr M. Panay N. Seitz C. Seymore S. Efficacy and Safety of Elinzanetant, a Selective Neurokinin-1,3 Receptor Antagonist for Vasomotor Symptoms: A Dose-Finding Clinical Trial (SWITCH-1) Menopause 2023 30 239 246 10.1097/GME.0000000000002138 36720081 PMC9970022

267. Definition of Elinzanetant—NCI Drug Dictionary—NCI Available online: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/elinzanetant (accessed on 25 October 2025)

268. Panay N. Joffe H. Maki P.M. Nappi R.E. Pinkerton J.V. Simon J.A. Soares C.N. Thurston R.C. Francuski M. Caetano C. Elinzanetant for the Treatment of Vasomotor Symptoms Associated with Menopause: A Phase 3 Randomized Clinical Trial JAMA Intern. Med. 2025 185 1319 1327 10.1001/jamainternmed.2025.4421 40920404 PMC12418220

269. Rottmann A. Peters M. Engelen A. Bordini E. Davalli S. Cufari D. Trower M. Novel Dual Nk-1/Nk-3 Receptor Antagonists WO2024188935A1 11 March 2024

270. Mihălțan F.-D. Ulmeanu R. Constantin A.-A. Brensocatib—Another Therapeutic “Window of Opportunity” for Patients with Bronchiectasis J. Clin. Med. 2026 15 1257 10.3390/jcm15031257 41682938 PMC12898296

271. Furqan M. Haider M.U. Binte Rahim S. Brensocatib—An Editorial on the New Chapter in Noncystic Fibrosis Bronchiectasis Treatment Ann. Med. Surg. 2025 87 6964 6966 10.1097/MS9.0000000000003976 41180673 PMC12577892

272. Targeting Neutrophilic Inflammation in Obstructive Airway Disease—A Narrative Review of Brensocatib Therapy—Respiratory Medicine Available online: https://www.resmedjournal.com/article/S0954-6111(25)00306-3/fulltext (accessed on 27 February 2026) 10.1016/j.rmed.2025.108243 40614835

273. Chalmers J.D. Burgel P.-R. Daley C.L. De Soyza A. Haworth C.S. Mauger D. Loebinger M.R. McShane P.J. Ringshausen F.C. Blasi F. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis N. Engl. J. Med. 2025 392 1569 1581 10.1056/NEJMoa2411664 40267423

274. Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986)|Journal of Medicinal Chemistry Available online: https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01127 (accessed on 17 June 2026) 10.1021/acs.jmedchem.6b01127 27690432

275. Lee A. Zongertinib: First Approval Drugs 2026 86 397 401 10.1007/s40265-025-02265-y 41549172

276. Haider E. Ahmad N. Taj J. Ekouo J. Clinical Significance of Zongertinib in HER2-Mutated Non-Small Cell Lung Cancer: Advancing Targeted Therapy Options Ann. Med. Surg. 2026 88 2108 2109 10.1097/MS9.0000000000004571 41675765 PMC12889504

277. Wilding B. Woelflingseder L. Baum A. Chylinski K. Vainorius G. Gibson N. Waizenegger I.C. Gerlach D. Augsten M. Spreitzer F. Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers Cancer Discov. 2025 15 119 138 10.1158/2159-8290.CD-24-0306 39248702 PMC11726021

278. [1,3]DIAZINO[5,4-d]Pyrimidines AS HER2 Inhibitors WO2021213800 28 October 2021 Available online: https://patentscope.wipo.int/search/en/WO2021213800 (accessed on 17 June 2026)

279. Blair H.A. Dordaviprone: First Approval Drugs 2026 86 101 109 10.1007/s40265-025-02252-3 41138047

280. Honnanayakanavar J.M. Nanubolu J.B. Suresh S. Tandem Copper Catalyzed Regioselective N-Arylation–Amidation: Synthesis of Angularly Fused Dihydroimidazoquinazolinones and the Anticancer Agent TIC10/ONC201 Org. Biomol. Chem. 2021 19 8497 8501 10.1039/D1OB01561C 34546282

281. Jawaid Z. Khalid M. Waafira A. Delgocitinib 2% Cream: A Promising FDA-Approved Therapy for Moderate-to-Severe Chronic Hand Eczema Ann. Med. Surg. 2025 87 6916 6917 10.1097/MS9.0000000000003771 41181467 PMC12577888

282. Abdelhalim A. Yilmaz O. Elshaikh Berair M. Torres T. Topical Delgocitinib for the Treatment of Chronic Hand Eczema J. Dermatol. Treat. 2025 36 2479126 10.1080/09546634.2025.2479126 40096745

283. Morita K. Umekubo N. Matsuzaki H. Tsutsumi K. Yokoshima S. Stereoselective Synthesis of Delgocitinib and Its Diastereomer Using Organocatalyzed Michael Addition Org. Lett. 2025 27 6789 6793 10.1021/acs.orglett.5c01960 40515702

284. FDA Approves Sebetralstat for Hereditary Angioedema Available online: https://www.ajmc.com/view/fda-approves-sebetralstat-for-hereditary-angioedema (accessed on 26 July 2025)

285. Aygören-Pürsün E. Zanichelli A. Cohn D.M. Cancian M. Hakl R. Kinaciyan T. Magerl M. Martinez-Saguer I. Stobiecki M. Farkas H. An Investigational Oral Plasma Kallikrein Inhibitor for On-Demand Treatment of Hereditary Angioedema: A Two-Part, Randomised, Double-Blind, Placebo-Controlled, Crossover Phase 2 Trial Lancet 2023 401 458 469 10.1016/S0140-6736(22)02406-0 36774155

286. Bygum A. Busse P. Caballero T. Maurer M. Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema Front. Med. 2017 4 212 10.3389/fmed.2017.00212 29255709 PMC5722805

287. Feener E.P. Davie R.L. Murugesan N. Pethen S.J. Hampton S.L. Smith M.D. Audhya P.K. Yea C.M. Sebetralstat: A Rapidly Acting Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Drugs Drug Candidates 2024 3 328 341 10.3390/ddc3020019

288. Farkas H. Balla Z. An Evaluation of Sebetralstat as the First Oral On-Demand Therapy for Hereditary Angioedema Expert Opin. Pharmacother. 2025 26 685 693 10.1080/14656566.2025.2482737 40110977

289. Dhillon S. Sunvozertinib: First Approval Drugs 2023 83 1629 1634 10.1007/s40265-023-01959-5 37962831

290. FDA Approves Sunvozertinib in Non–Small Cell Lung Cancer Available online: https://www.ajmc.com/view/fda-approves-sunvozertinib-in-non-small-cell-lung-cancer (accessed on 25 July 2025)

291. Malik F.S. Naveed F. Khan A. Fatima M. Acoltremon and the TRPM8 Frontier: A New Chapter in Dry Eye Disease Therapy Ann. Med. Surg. 2025 87 6256 6258 10.1097/MS9.0000000000003763 41181487 PMC12577975

292. Zhou Y. Zhang W. Sun F. Acoltremon: The First TRPM8 Agonist Approved for the Treatment of Dry Eye Disease Drug Discov. Ther. 2025 19 210 211 10.5582/ddt.2025.01048 40571589

293. Preparation of Key Intermediate Menthyl Formic Acid of WS Series Cooling Agent. Patent#CN117945886 Available online: https://www.medkoo.com/drug_syntheses/413 (accessed on 2 May 2026)

294. Abbas M. Ali Sami S.H. Gajdács M. Tariq M.J. Recent FDA-Approved Kinase Inhibitors for Cancer Therapy in 2025: A Comprehensive Review and Perspectives EXCLI J. 2025 24 1609 10.17179/EXCLI2025-8972 41584508 PMC12828158

295. Keam S.J. Atrasentan: First Approval Drugs 2025 85 1311 1317 10.1007/s40265-025-02208-7 40760295

296. Moedt E. Wasehuus V.S. Heerspink H.J.L. Selective Endothelin A Receptor Antagonism in Chronic Kidney Disease: Improving Clinical Application Nephrol. Dial. Transplant. 2025 40 i37 i46 10.1093/ndt/gfae214 39907539 PMC11795649

297. Hajra S. Aziz S.M. Jana B. Hazra S. Organocatalytic Enantioselective Conjugate Addition of Nitromethane to Benzylidene-2-Benzoyl Acetate: Asymmetric Synthesis of ABT—627, an Endothelin Receptor Antagonist Front. Chem. 2020 8 135 10.3389/fchem.2020.00135 32195223 PMC7066299

298. Keam S.J. Gepotidacin: First Approval Drugs 2025 85 1479 1485 10.1007/s40265-025-02214-9 40762778

299. Watkins R.R. Thapaliya D. Lemonovich T.L. Bonomo R.A. Gepotidacin: A Novel, Oral, ‘First-in-Class’ Triazaacenaphthylene Antibiotic for the Treatment of Uncomplicated Urinary Tract Infections and Urogenital Gonorrhoea J. Antimicrob. Chemother. 2023 78 1137 1142 10.1093/jac/dkad060 36883591

300. Widdowson K.L. Tricyclic Nitrogen Containing Compounds for Treating Neisseria Gonorrhoea Infection WO2016027249A1 25 February 2016

301. Lee A. Vimseltinib: First Approval Drugs 2025 85 985 989 10.1007/s40265-025-02191-z 40415163

302. Dou F. Lu D. Gao J. Vimseltinib: A Novel Colony Stimulating Factor 1 Receptor (CSF1R) Inhibitor Approved for Treatment of Tenosynovial Giant Cell Tumors (TGCTs) Intractable Rare Dis. Res. 2025 14 143 144 10.5582/irdr.2025.01010 40485889 PMC12143222

303. Aamir M.B. Kumari P. Altaf M.T. Naseer M.Q. Oduoye M.O. Adewole M.O. FDA Approves Journavx (Suzetrigine) as the First Non-Opioid Treatment for Moderate to Severe Acute Pain Ann. Med. Surg. 2025 87 7889 7890 10.1097/MS9.0000000000004078 41377229 PMC12688889

304. Hu S. Lyu D. Gao J. Suzetrigine: The First Nav1.8 Inhibitor Approved for the Treatment of Moderate to Severe Acute Pain Drug Discov. Ther. 2025 19 80 82 10.5582/ddt.2025.01010 40010720

305. A First-in-Class, FDA-Approved Non-Addictive NaV1.8 Inhibitor for Acute and Moderate Pain Available online: https://drughunter.com/molecule/suzetrigine-vx-548/ (accessed on 2 May 2026)

306. Suzetrigine Synthesis Available online: https://www.a2bchem.com/synthesisRoute/2649467-58-1 (accessed on 2 May 2026)

307. Harrison C. Process for the Synthesis of Substituted Tetrahydrofuran Modulators of Sodium Channels WO2022256660A1 8 December 2022

308. Shirley M. Elamipretide: First Approval Drugs 2026 86 377 383 10.1007/s40265-025-02269-8 41335372

309. Tung C. Varzideh F. Farroni E. Mone P. Kansakar U. Jankauskas S.S. Santulli G. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential Int. J. Mol. Sci. 2025 26 944 10.3390/ijms26030944 39940712 PMC11816484

310. Novak I. Chua P.J. Computational Study of Pharmacophores: β-Lactams J. Phys. Chem. A 2006 110 10521 10524 10.1021/jp063162b 16942059

311. Wei L. Malhotra S. Recent Development of Cyclic Amide (Pyridone/Lactam) Moiety Containing Heterocycles as Protein Kinase Inhibitors Curr. Med. Chem. 2010 17 234 253 10.2174/092986710790149747 20214566

312. Szostak M. Aubé J. Chemistry of Bridged Lactams and Related Heterocycles Chem. Rev. 2013 113 5701 5765 10.1021/cr4000144 24490625 PMC4155605

313. Turner J. Muraoka A. Bedenbaugh M. Childress B. Pernot L. Wiencek M. Peterson Y.K. The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition Front. Microbiol. 2022 13 807955 10.3389/fmicb.2022.807955 35401470 PMC8988990

314. Yang J. Zhu Q. Wu Y. Qu X. Liu H. Jiang B. Ge D. Song X. Utilization of Macrocyclic Peptides to Target Protein-Protein Interactions in Cancer Front. Oncol. 2022 12 992171 10.3389/fonc.2022.992171 36465350 PMC9714258